[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2828
1. Jones LC, Tefferi A, Vuong PT, Desmond JC, Hofmann WK, Koeffler HP: Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells; 2005 May;23(5):631-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays.
  • Agnogenic myeloid metaplasia (AMM) is a clonal stem cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis.
  • Therefore, the aim of this study was to characterize aberrant gene expression in CD34+ hematopoietic stem cells from patients with AMM.
  • We used oligonucleotide microarrays to analyze gene expression profiles in CD34+ hematopoietic stem cells from patients with AMM compared with expression in CD34+ cells from healthy individuals.
  • Using class membership prediction analysis, we identified 75 genes whose expression profiles can accurately differentiate AMM samples from the controls.
  • Using these 75 genes, we were able to discriminate patients with AMM from the controls by hierarchical clustering (Spearman's confidence correlation).
  • The predictive power of these genes was verified by applying the algorithm to an unknown test set containing expression data from eight additional CD34+ samples (four AMM, four control).
  • Our results indicate that a subset of genes may be used to differentiate patients with AMM from healthy individuals.
  • Furthermore, we identify 95 genes whose aberrant expression may be involved in AMM.
  • [MeSH-major] Antigens, CD34. Gene Expression Regulation. Hematopoietic Stem Cells / metabolism. Oligonucleotide Array Sequence Analysis. Primary Myelofibrosis / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849170.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA-75956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


2. Stanko JP, Enoch RR, Rayner JL, Davis CC, Wolf DC, Malarkey DE, Fenton SE: Effects of prenatal exposure to a low dose atrazine metabolite mixture on pubertal timing and prostate development of male Long-Evans rats. Reprod Toxicol; 2010 Dec;30(4):540-9
Hazardous Substances Data Bank. ATRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study examines the postnatal reproductive development of male rats following prenatal exposure to an atrazine metabolite mixture (AMM) consisting of the herbicide atrazine and its environmental metabolites diaminochlorotriazine, hydroxyatrazine, deethylatrazine, and deisopropylatrazine.
  • Pregnant Long-Evans rats were treated by gavage with 0.09, 0.87, or 8.73mg AMM/kg body weight (BW), vehicle, or 100mg ATR/kg BW positive control, on gestation days 15-19.
  • Preputial separation was significantly delayed in 0.87 mg and 8.73mg AMM-exposed males.
  • AMM-exposed males demonstrated a significant treatment-related increase in incidence and severity of inflammation in the prostate on postnatal day (PND) 120.
  • A dose-dependent increase in epididymal fat masses and prostate foci were grossly visible in AMM-exposed offspring.
  • These results indicate that a short, late prenatal exposure to mixture of chlorotriazine metabolites can cause chronic prostatitis in male LE rats.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Toxicol Sci. 1999 Nov;52(1):68-79 [10568700.001]
  • [Cites] Environ Monit Assess. 2009 Aug;155(1-4):281-307 [18677547.001]
  • [Cites] Toxicol Sci. 2000 Feb;53(2):297-307 [10696778.001]
  • [Cites] Toxicol Sci. 2000 May;55(1):152-61 [10788570.001]
  • [Cites] Toxicol Sci. 2000 Nov;58(1):50-9 [11053540.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):366-76 [11099648.001]
  • [Cites] J Androl. 2001 Jan-Feb;22(1):142-8 [11191080.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):198-206 [12011479.001]
  • [Cites] J Reprod Immunol. 2003 Feb;58(1):1-26 [12609522.001]
  • [Cites] Environ Sci Technol. 2003 Mar 1;37(5):944-50 [12666925.001]
  • [Cites] Toxicol Sci. 2003 Nov;76(1):190-200 [12970575.001]
  • [Cites] Toxicol Pathol. 2004 Jan-Feb;32(1):79-90 [14713552.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Feb 15;195(1):23-34 [14962502.001]
  • [Cites] Invest Urol. 1976 Jul;14(1):20-2 [955845.001]
  • [Cites] Biol Reprod. 1977 Sep;17(2):298-303 [889997.001]
  • [Cites] J Steroid Biochem. 1979 Jul;11(1C):833-8 [491646.001]
  • [Cites] Prog Clin Biol Res. 1981;75B:9-18 [6275416.001]
  • [Cites] J Steroid Biochem. 1987;27(4-6):1095-100 [3695505.001]
  • [Cites] J Steroid Biochem. 1989 Jul;33(1):141-6 [2761262.001]
  • [Cites] Endocrinology. 1977 Mar;100(3):729-37 [401024.001]
  • [Cites] J Toxicol Environ Health. 1994 Oct;43(2):169-82 [7932847.001]
  • [Cites] Reprod Toxicol. 1996 Jul-Aug;10(4):257-64 [8829248.001]
  • [Cites] Steroids. 1999 Sep;64(9):672-8 [10503727.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2005 Jun;74(3):277-85 [15954088.001]
  • [Cites] Chem Res Toxicol. 2006 May;19(5):692-700 [16696572.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S18-24 [16690811.001]
  • [Cites] Int J Occup Environ Health. 2006 Jul-Sep;12(3):260-7 [16967834.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Feb 1;218(3):238-48 [17204298.001]
  • [Cites] Environ Health Perspect. 2007 Apr;115(4):541-7 [17450222.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2007 Apr;80(2):98-112 [17443714.001]
  • [Cites] Endocrinology. 2007 Jul;148(7):3185-95 [17431008.001]
  • [Cites] J Androl. 2008 May-Jun;29(3):304-11 [17978342.001]
  • [Cites] Environ Health Perspect. 2008 Jul;116(7):923-9 [18629315.001]
  • [ErratumIn] Reprod Toxicol. 2011 Jul;32(1):146-7
  • (PMID = 20727709.001).
  • [ISSN] 1873-1708
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Herbicides; 0 / Pesticide Residues; QJA9M5H4IM / Atrazine
  • [Other-IDs] NLM/ NIHMS230835; NLM/ PMC2993819
  •  go-up   go-down


3. Qie YQ, Wang JL, Liu W, Shen H, Chen JZ, Zhu BD, Xu Y, Zhang XL, Wang HH: More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. Scand J Immunol; 2009 Apr;69(4):342-50
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunogenicity of the recombinant Bacille Calmette-Guerin: rBCG-Ag85B-Mpt64(190-198)-Mtb8.4 (rBCG-AMM) was evaluated in our previous study.
  • This paper compares the protective efficacy of rBCG-AMM, rBCG-A which overexpresses Ag85B and BCG in C57BL/6 mice.
  • There was no significant difference in proliferation characteristics among rBCG-AMM, rBCG-A and BCG.
  • The growth characteristics of rBCG-AMM in host tissue were identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B-Mpt64(190-198)-Mtb8.4 fusion protein.
  • The protective experiment demonstrated that rBCG-AMM could confer similar or even better protective efficacy against Mycobacterium tuberculosis infection compared with BCG or rBCG-A as evaluated by bacterial organ loads, lung histopathology and net weight gain or loss.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284499.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / BCG Vaccine; 0 / Recombinant Fusion Proteins; 0 / Vaccines, Synthetic
  •  go-up   go-down


Advertisement
4. Hillengass J, Zechmann C, Bäuerle T, Wagner-Gund B, Heiss C, Benner A, Ho A, Neben K, Hose D, Kauczor HU, Goldschmidt H, Delorme S, Moehler T: Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res; 2009 May 1;15(9):3118-25
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
  • PURPOSE: The aim of our study was to investigate whether dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows visualization of changes in microcirculation between healthy controls on the one side and early/advanced stages of plasma cell disease on the other.
  • EXPERIMENTAL DESIGN: We examined a group of 222 individuals consisting of 60 patients with monoclonal gammopathy of undetermined significance (MGUS), 65 patients with asymptomatic multiple myeloma (aMM), 75 patients with newly diagnosed symptomatic MM (sMM), and 22 healthy controls with DCE-MRI of the lumbar spine.
  • RESULTS: A continuous increase in microcirculation parameters amplitude A and exchange rate constant kep reflecting vascular volume and permeability, respectively, was detected from normal controls over MGUS and aMM to sMM.
  • For A and kep, significant differences were found between controls and aMM (P = 0.03 and P = 0.004, respectively) as well as controls and sMM (P = 0.001 and P < 0.001, respectively).
  • Although diffuse microcirculation patterns were found in healthy controls as well as MGUS and MM, a pattern with focal hotspots was exclusively detected in 42.6% of sMM and in 3 MGUS and 3 aMM patients.
  • MGUS and aMM patients with increased microcirculation patterns showed significantly higher bone marrow plasmocytosis compared with patients with a low microcirculation pattern.
  • Pathologic DCE-MRI findings correlate with adverse prognostic factors and DCE-MRI identifies a distinct group of patients with increased microcirculation parameters in aMM and MGUS patients.
  • [MeSH-major] Bone Marrow / blood supply. Contrast Media. Magnetic Resonance Imaging. Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366830.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Scolozzi P, Herzog G, Jaques B: Re: Shehata EAA, Medra AMM. Modified bimaxillary distraction osteogenesis: A technique to correct facial asymmetry. Br J Oral Maxillofac Surg 2006;45:471-7. Br J Oral Maxillofac Surg; 2008 Mar;46(2):170-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Shehata EAA, Medra AMM. Modified bimaxillary distraction osteogenesis: A technique to correct facial asymmetry. Br J Oral Maxillofac Surg 2006;45:471-7.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Oral Maxillofac Surg. 2007 Sep;45(6):471-7 [17161890.001]
  • (PMID = 17618714.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Scotland
  •  go-up   go-down


6. Frank P, Benfatto M, Hedman B, Hodgson KO: Solution [Cu(amm)]2+ is a strongly solvated square pyramid: a full account of the copper K-edge XAS spectrum within single-electron theory. Inorg Chem; 2008 May 19;47(10):4126-39
Hazardous Substances Data Bank. Ammonia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solution [Cu(amm)]2+ is a strongly solvated square pyramid: a full account of the copper K-edge XAS spectrum within single-electron theory.
  • The solution structure of Cu(II) in 4 M aqueous ammonia, [Cu(amm)](2+), was assessed using copper K-edge extended X-ray absorption fine structure (EXAFS) and Minuit XANes (MXAN) analyses.
  • Each approach converged to the same axially elongated square pyramid, 4 x Cu-Neq=2.00+/-0.02 A and 1 x Cu-Nax=2.16+/-0.02 A (EXAFS) or 2.20+/-0.07 A (MXAN), with strongly localized solvation shells.
  • The prominent shoulder and duplexed maximum of the rising K-edge XAS of [Cu(amm)](2+) primarily reflect the durable and well-organized solvation shells, not found around [Cu(H2O)5](2+), rather than two-electron shakedown transitions.
  • Not accounting for solvent scattering thus may confound XAS-based estimates of metal-ligand covalency.
  • [Cu(amm)](2+) continues the dissymmetry previously found for the solution structure of [Cu(H2O)5](2+), again contradicting the rack-bonding theory of blue copper proteins.

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426203.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR001209; United States / NCRR NIH HHS / RR / RR-01209; United States / NCRR NIH HHS / RR / RR001209
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations, Divalent; 0 / Solutions; 7664-41-7 / Ammonia; 789U1901C5 / Copper
  •  go-up   go-down


7. Guliants VV, Bhandari R, Hughett AR, Bhatt S, Schuler BD, Brongersma HH, Knoester A, Gaffney AM, Han S: Probe molecule chemisorption-low energy ion scattering study of surface active sites present in the orthorhombic Mo-V-(Te-Nb)-O catalysts for propane (amm)oxidation. J Phys Chem B; 2006 Mar 30;110(12):6129-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probe molecule chemisorption-low energy ion scattering study of surface active sites present in the orthorhombic Mo-V-(Te-Nb)-O catalysts for propane (amm)oxidation.
  • These orthorhombic phases exhibited vastly different behavior in propane (amm)oxidation reactions and, therefore, represented highly promising model systems for the study of the surface active sites.
  • These findings strongly suggested that the bulk orthorhombic Mo-V-Te-Nb-O structure may function as a support for the unique active and selective surface monolayer in propane (amm)oxidation.
  • Finally, the present study strongly indicated that chemical probe chemisorption combined with low energy ion scattering (LEIS) is a novel and highly promising surface characterization technique for the investigation of the active surface sites present in the bulk mixed metal oxides.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553426.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Lazarević V, Tiodorović J, Tiodorović-Zivković D, Stanojević M, Popović D, Janković A: Immunophenotyping of amelanotic melanoma. A case report. Acta Dermatovenerol Alp Pannonica Adriat; 2006 Sep;15(3):141-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of amelanotic melanoma. A case report.
  • Amelanotic malignant melanoma (AMM) is a subtype of cutaneous melanoma with little or no pigment upon visual inspection.
  • The lack of pigmentation is the reason for late diagnosis of lesions and a poor prognosis.
  • We report a case of a 55-year-old female with an AMM diagnosed by immunophenotyping.
  • So far there are no signs of a recurrence.
  • In doubtful cases, immunophenotyping with monoclonal antibodies HMB-45 and S-100 is important for confirming the correct diagnosis of AMM.
  • [MeSH-major] Melanoma, Amelanotic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antibodies / therapeutic use. Antibodies, Monoclonal / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunophenotyping. Keratins / immunology. Middle Aged. S100 Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053850.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


9. Martin-Eauclaire MF, Alami M, Giamarchi A, Missimilli V, Rosso JP, Bougis PE: A natural anatoxin, Amm VIII, induces neutralizing antibodies against the potent scorpion alpha-toxins. Vaccine; 2006 Mar 15;24(12):1990-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A natural anatoxin, Amm VIII, induces neutralizing antibodies against the potent scorpion alpha-toxins.
  • In this study, we have used Amm VIII, a natural anatoxin from the scorpion Androctonus mauretanicus mauretanicus, to elicit specific polyclonal antibodies in rabbit.
  • We have shown that the anti-Amm VIII serum prevents the association of 125I-AaH II with its receptor and is able to remove 125I-AaH II already bound to its site (the half-life of the complex 125I-AaH II-receptor site was 12 min in the absence of anti-Amm VIII serum but decreased to only 2 min in the presence of anti-Amm VIII serum).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325311.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Antibodies; 0 / Scorpion Venoms; 0 / Toxoids; 0 / Vaccines, Synthetic
  •  go-up   go-down


10. Alami M, Céard B, Legros C, Bougis PE, Martin-Eauclaire MF: Genomic characterisation of the toxin Amm VIII from the scorpion Androctonus mauretanicus mauretanicus. Toxicon; 2006 Apr;47(5):531-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic characterisation of the toxin Amm VIII from the scorpion Androctonus mauretanicus mauretanicus.
  • The genomic DNA sequence encoding the scorpion toxin Amm VIII was amplified from genomic DNA of the scorpion Androctonus mauretanicus mauretanicus from Morocco, subcloned and sequenced.
  • An intron, with a high A+T content (73.5%), split a Gly codon at the end of the precursor signal peptide and the consensus GT/AG splice junction was identified in the Amm VIII gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533515.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Scorpion Venoms
  •  go-up   go-down


11. Oyama MA, Sisson DD: Assessment of cardiac chamber size using anatomic M-mode. Vet Radiol Ultrasound; 2005 Jul-Aug;46(4):331-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anatomic M-mode (AMM) is an echocardiographic technique that is capable of generating M-mode studies from two-dimensional (2D) cine loops.
  • Unlike conventional M-mode (CMM) whose scan line must lie along the axis of the ultrasound signal, AMM produces M-mode studies independent of the orientation of the ultrasound beam.
  • We sought to determine the ability of AMM to measure cardiac dimensions in normal dogs and to assess the accuracy and variability of AMM and CMM vs. 2D measurements.
  • Thirty-eight healthy dogs underwent physical exam and 2D, CMM, and AMM echocardiographic studies.
  • Results of the AMM and CMM study were compared with the 2D study via linear regression and calculation of a coefficient of correlation.
  • AMM increased the level of correlation with both the left ventricular dimensions and LAD.
  • Bland-Altman analysis revealed that AMM increased the level of agreement with 2D measurements and CMM greatly underestimated LAD vs. AMM.
  • In healthy dogs, cardiac AMM measurements are associated with greater accuracy and less variability than CMM.
  • AMM has the potential to improve quantification of cardiac dimensions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229436.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Alvarenga L, Moreau V, Felicori L, Nguyen C, Duarte C, Chavez-Olortegui C, Molina F, Martin-Eauclaire MF, Granier C: Design of antibody-reactive peptides from discontinuous parts of scorpion toxins. Vaccine; 2010 Jan 22;28(4):970-80
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Amm VIII protein was previously isolated from the venom of the scorpion Androctonus mauretanicus mauretanicus.
  • Despite 87% identity with AaH II, the most toxic alpha-type scorpion toxin, Amm VIII is not toxic to mice.
  • However, antisera against Amm VIII protect mice from AaH II lethal action.
  • Here, we report that the Amm VIII protein elicits antibodies that only recognize discontinuous-type epitopes since we could not observe any antibody binding to overlapping 12-mer peptides covering the whole Amm VIII sequence.
  • By using a new bioinformatic tool, 24 peptides mimicking discontinuous regions of Amm VIII were designed in silico, then prepared by Spot synthesis.
  • Seven of these discontinuous-continuous peptides were recognized by anti-Amm VIII antibodies.
  • Analysis of the 3D location of the segments that compose the antigenically reactive discontinuous-continuous peptides, allowed us to group those antigenic segments into three regions of Amm VIII, putatively corresponding to discontinuous antigenic regions of alpha-type scorpion toxins.
  • Anti-Amm VIII antibodies were also found to cross-react towards several of the discontinuous-continuous peptides designed from the AaH II structure, pointing to a possible involvement of the corresponding discontinuous epitopes in the capacity displayed by anti-Amm VIII antibodies to neutralize AaH II.
  • The position of the reactive segments in the structural context of scorpion toxins highlights the antigenic properties of the Amm VIII anatoxin and concurs to explain the capacity of anti-Amm VIII antibodies to neutralize the potent AaH II toxin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19962461.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Antibodies, Neutralizing; 0 / Antitoxins; 0 / Epitopes; 0 / Scorpion Venoms
  •  go-up   go-down


13. Hemavathy KC, Chang TH, Zhang H, Charles W, Goldberg A, Aithal S, Novetsky AD, Wang JC: Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. Leuk Res; 2006 Jan;30(1):47-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation.
  • Agnogenic myeloid metaplasia (AMM) is characterized by bone marrow fibrosis and enhanced proliferation of megakaryocytes and CD34+ cells.
  • We have analyzed the factors that could lead to reduced expression of TGF beta1RII in CD34+ cells of AMM patients.
  • Our results demonstrate absence of mutations in the coding region and the promoter of this gene and absence of CpG methylation of its promoter in AMM patients.
  • Further studies on transcriptional regulation of TGF beta1RII involving its cis-regulatory elements, the interacting transcription factors and their association with HDAC will provide valuable information on the pathogenesis of AMM and are under current investigation.
  • [MeSH-major] DNA Methylation. Gene Expression Regulation / genetics. Mutation. Primary Myelofibrosis / metabolism. Receptors, Transforming Growth Factor beta / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054691.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transcription Factors; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


14. Zhu Bd, Qie Yq, Wang Jl, Zhang Y, Wang Qz, Xu Y, Wang Hh: Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm; 2007 Jun;66(3):318-26
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To develop novel delivery system for tuberculosis (TB) subunit vaccine, biodegradable chitosan microspheres were prepared and used to deliver a fusion protein, Ag85B-MPT64(190-198)-Mtb8.4 (AMM for short), made from three Mycobacterium tuberculosis genes.
  • AMM-loaded microspheres were first characterized for their morphology, size, zeta potential, loading efficiency, and in vitro release of AMM.
  • C57BL/6 mice were immunized at weeks 1, 3 and 5 subcutaneously with AMM formulated in chitosan microspheres, in incomplete Freund's adjuvant (IFA), or in phosphate-buffered saline (PBS), respectively.
  • It was shown that the microspheres bound AMM quite efficiently (loading efficiency: >99%).
  • AMM-loaded chitosan microspheres were observed as aggregated shapes with the average particle size of 5.78+/-0.65 microm and zeta potential of 32.77+/-1.51 mV.
  • Following subcutaneous administration, splenocytes immunized with AMM in chitosan microspheres produced higher levels of IFN-gamma compared to administration of AMM in PBS upon stimulation with Ag85B and synthetic peptide MPT64(190-198).
  • The levels of Ag85B-specific IgG (H+L), IgG1 and IgG2a in sera of mice immunized with AMM in chitosan microspheres were also higher than those with AMM in PBS.
  • These results indicate that chitosan microspheres when used as a carrier for fusion protein AMM could elicit strong humoral and cell-mediated immune responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280823.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Cytokines; 0 / Epitopes, T-Lymphocyte; 0 / Recombinant Fusion Proteins; 0 / Tuberculosis Vaccines; 0 / Vaccines, Subunit; 0 / Vaccines, Synthetic; 82115-62-6 / Interferon-gamma; 9012-76-4 / Chitosan; EC 2.3.- / Acyltransferases; EC 2.3.1.- / antigen 85B, Mycobacterium tuberculosis
  •  go-up   go-down


15. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve S, Sledge G, Eastern Cooperative Oncology Group: Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This multi-institutional, single-stage, non-comparative, randomized phase II study tested the EGFR tyrosine kinase inhibitor gefitinib 250 mg daily PO plus endocrine therapy with either anastrozole 1 mg/day PO (AG Arm) versus fulvestrant 250 mg IM every 4-weeks (FG Arm).
  • Eligible pts were postmenopausal women with ER+ and/or PgR+ measurable metastatic breast cancer with no prior endocrine therapy for metastatic disease, no prior adjuvant AI or fulvestrant, no more than two chemotherapy regimens for metastatic disease, ECOG status 0-2, no CNS metastasis, and adequate bone marrow, liver, and renal function.
  • Primary endpoint was RECIST determined clinical benefit (CR+PR+SD for ≥6 mos) and secondary endpoints were toxicity and interaction of biomarkers with clinical benefit.
  • Treatment groups were balanced for race, age, ECOG status, and sites of disease.
  • Median follow-up is 35 mos.
  • Treatment was terminated for disease progression in 74% v 75%, toxicity 7% v 10%, death 1% v 3%, withdrawal 8% v 1%, and other 3% v 7% in the AG v FG arms, respectively.
  • Response rates are CR 3% v 4%, PR 21% v 17%, SD for ≥6 mos 18% v 17% for AG v FG.
  • Median PFS is 5.7 mos v 5.2 mos and median OS is 30.2 mos v 23.8 mos for AG v FG, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wu Y, Kwok Y, Mirmiran A, Goloubeva O, Mannuel H, Dawson N, Amin P, Hussain A: Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5122 Background: EBRT with ADT (4 mos to 2-3 yrs) is standard treatment for high risk PC.
  • Treatment included ADT (4 or 24 mos, preplanned based on clinical presentation), P (40, 50, or 60 mg/m2/wk) x 7 with EBRT, and whole pelvis EBRT 45 Gy with 19.8 Gy boost (total 64.8 Gy) to prostate bed in RP pts and 25.2 Gy boost (total 70.2 Gy) to prostate in LAPC pts.
  • ADT for 4 mos was given in 29 pts and for 24 mos in 30 pts.
  • Median duration of f/u was 75.3 mos, OS 78%, biochemical progression 24/59 (41%) pts, clinical progression 11/59 (19%) pts.
  • Time to biochemical progression was similar between RP vs. LAPC (p = 0.17), between ADT 4 mos vs. 24 mos (p = 0.61), and between AA vs. W (p = 0.54).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964408.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ougari KE, Taneja C, Sofrygin O, Kaura S, Delea T: Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective. J Clin Oncol; 2009 May 20;27(15_suppl):557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 557 Background: The Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) examined the efficacy of 3 years (yrs) of treatment with goserelin in combination with ET (anastrozole or tamoxifen) with or without ZOL 4 mg q6 mos in 1,803 premenopausal women with EBC (median age 45 yrs).
  • After a median follow-up of 47.8 mos (max 84 mos), risk of disease-free survival (DFS) events was reduced by 36% (HR = 0.64; p = 0.01) in patients (pts) who received ZOL (ZOL+ET) compared with those who did not (ET).
  • A Canadian healthcare system perspective and a lifetime timeframe were used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960672.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mesa RA, Kantarjian H, Tefferi A, Cheville A, Pardanani A, Levy R, Erickson-Viitanen S, Thomas D, Cortes J, Borthakur G, Verstovsek S: Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT). J Clin Oncol; 2009 May 20;27(15_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT).
  • : 7083 Background: Patients with Myelofibrosis (MF) suffer from significant fatigue, constitutional symptoms and splenomegaly (Mesa et. al.
  • The 6MWT was administered in standardized fashion (American Thoracic Society: observed laps of a 30 - 35 meter long course, indoors, level, without encouragement), and then repeated for further validation.
  • Cancer 1999) embedded in the MFSAF) showed patients with a higher BFI (i.e., more fatigued) had more impairment in the 6MWT than those with low BFI scores.
  • Validation of the ability of the 6MWT to measure functional improvements in MF patients as a response to novel therapy trials is planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Obasaju CK, Raju RN, Stinchcombe T, Couch LS, Jotte R, Kocs DM, Wang Y, Bromund J, Treat J, Socinski MA: Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).
  • In the TAX 326 trial, D + cisplatin was associated with a median survival of 11.3 mos vs. 10.1 mos for vinorelbine + cisplatin (P=.04).
  • Pts were equally randomized to 3 arms: (A) P 500 mg/m<sup>2</sup> and Cb AUC 6 every 3 wks × 6 cycles with E given orally as a loading dose of 1200 mg or 1125 mg followed by 500 mg daily until disease progression;.
  • CONCLUSIONS: First-line treatment with PCb was associated with a significantly longer overall survival than DCb in advanced or metastatic NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962857.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol; 2009 May 20;27(15_suppl):4508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Treatment-naïve patients with histologically confirmed locally inoperable or metastasized well-differentiated NETs and a Karnofsky index >60 were randomized to receive either octreotide LAR 30 mg/month (mo) or placebo for 18 mos, or until tumor progression or death.
  • The primary endpoint was median time to tumor progression.
  • Secondary endpoints included objective tumor response rate (WHO criteria), measured every 3 mos, as well as symptom control and overall survival.
  • Median time to tumor progression in the octreotide LAR and placebo groups were 14.3 mos and 6 mos, respectively (HR: 0.34; 95% CI: 0.20-0.59; P=0.000072).
  • After 6 mos of treatment, stable disease was seen in 67% and 37.2% of patients treated with octreotide LAR and placebo, respectively.
  • Octreotide LAR demonstrates substantial tumor control and shows a more favorable antiproliferative response than placebo as two-thirds of patients treated with octreotide LAR achieved stable disease at 6 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Renouf DJ, Lim HJ, Speers C, Villa D, Gill S, Blanke CD, O'Reilly SE, Kennecke H: Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study. J Clin Oncol; 2009 May 20;27(15_suppl):4114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was OS of all pts within each cohort.
  • Median age at diagnosis of MCRC was 68y in 2003/04 and 69y in 2006.
  • Median follow up time was 47.3 and 21.4 mos respectively.
  • Median OS significantly improved for the entire cohort (13.8 to 17.3 mos, p<0.001).
  • Median OS for pts who received ST for MCRC improved (18.6 to 23.6 mos, p=0.001).
  • Median OS for pts who did not receive ST did not change (6.1 to 5.9 mos, p=0.65).
  • Median OS for pts <70 who received ST for MCRC improved (20.3 to 26.5 mos, p = 0.002).
  • Median OS for pts ≥70 who received ST for MCRC improved (16.5 to 19.9 mos), but this was not significant (p=0.16).
  • The improvement in survival appears to be limited to pts treated with ST for metastatic disease.
  • On a population basis, the addition of bev to CT is associated with a significant improvement in OS in MCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961224.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Carneiro BA, Bahary N, Lembersky B, Fakih M, Krishnamurthi SS, Lancaster S, Pinkerton R, Crandall T, Potter D, Ramanathan RK: Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):e15088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC).
  • Our study investigated the efficacy and safety of a biweekly I + C combination in patients (pts) with mCRC.
  • METHODS: mCRC pts who failed 1st line fluoropyrimidine/oxaliplatin regimens and had not received I or C, were eligible for this open label phase II trial with response rate (RR) as the primary end-point and planned sample size of 31 patients to achieve a 25% RR with 80% power.
  • Median OS 11.1 mos (95% CI 6.0-15.1) and TTP 2.4 mos (95% CI 1.4-NA).
  • The OS and TTP are consistent with those reported previously (Martin et al Brit J Cancer 2008, Pfeiffer P et al Ann Oncol 2008), supporting biweekly I + C as a convenient second-line regimen in mCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964555.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Wesolowski R, Shealy AG, Tao J, Moore HC: Differential outcomes in patients treated with endocrine therapy for early or locally advanced breast cancer based on BRCA mutation status. J Clin Oncol; 2009 May 20;27(15_suppl):e22065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Through an IRB approved registry, breast cancer patients tested for BRCA1 and BRCA2 mutations and treated with endocrine therapy for hormone-receptor positive non-metastatic disease were identified.
  • Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS) respectively.
  • RESULTS: Of 115 breast cancer patients tested for BRCA mutations, 63 met the inclusion criteria of whom 16 patients were BRCA 1 or 2 mutation positive and 47 were negative.
  • In the BRCA(+) group, 14 patients (87.5%) had stage I-III disease at diagnosis.
  • In the BRCA(-) group, 5 patients (10.6%) had stage 0 disease while 41 patients (87.2%) had stage I-III disease at diagnosis.
  • Stage at diagnosis was unavailable for 2 BRCA(+) and 1 BRCA(-) patients.
  • Both groups were similar with respect to Her-2 expression status, history of ovarian suppression, age of diagnosis, and age of menopause.
  • Median follow up was 76.1 mos in BRCA(+) and 62.9 mos in BRCA(-) group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963208.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Krupitskaya Y, Ganjoo K, Lavori PW, Kumar A, Clement-Duchene C, Zhao G, Padda S, San Pedro-Salcedo M, Wakelee HA: A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC).
  • Gemcitabine/carboplatin (GC) has equivalent efficacy to PC with a different toxicity profile.
  • B was then continued q21d until disease progression or unacceptable toxicity.
  • G3/G4 non-hematologic AEs included dyspnea (6%/2%), bacterial pneumonia (4%/0) hypertension (4%/2%), 1G3 wound dehiscence, 1G4 MI, 1G3 transaminitis and hyperbilirubinemia, 1G3 proteinuria and 1G3 leucocyturia.
  • 17/44 (38.6%) pts have died with median overall survival (mOS) not reached but preliminarily estimated at 16.7mo [95%CI 13.4mo-inf].
  • CONCLUSIONS: Treatment with GCB has an acceptable toxicity profile with promising mOS despite a low RR and frequent dose reductions in a population with a high proportion of non-smokers and women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962585.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hoshimoto S, Shingai T, Wang H, Elashhoff RM, Morton DL, Hoon DS, MMAIT-IV Clinical Trial Group Centers: Validation of a multimarker blood assay for postoperative assessment of stage IV melanoma patients in a prospective international phase III trial. J Clin Oncol; 2009 May 20;27(15_suppl):9045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a multimarker blood assay for postoperative assessment of stage IV melanoma patients in a prospective international phase III trial.
  • : 9045 Background: Currently there are no validated prognostic molecular biomarkers for assessment of outcome after complete resection of stage IV melanoma patients.
  • To validate blood molecular biomarkers for prognostic value and monitoring of these patients, we evaluated the clinical utility of a multimarker quantitative reverse-transcription PCR (qRT-PCR) for detecting circulating tumor cells (CTC) of patients blood enrolled in a multicenter international (29 sites) phase III trial of postoperative adjuvant therapy.
  • After complete metastasectomy, AJCC stage IV patients underwent immunotherapy with bacille Calmette-Guerin (BCG) plus placebo or BCG plus melanoma vaccine.
  • Median clinical follow-up time was 21.8 and 24.2 mos. for disease-free survival (DFS) and overall survival (OS), respectively.
  • In serial-bleeds (pretreatment, mos 1 and 3) analysis of 214 patients, biomarker-negative patients had significantly higher OS than patients with 1-2 positive- or 3 positive-biomarkers (risk ratio 2.37, 95% CI 1.14 - 4.94, P=0.021; and risk ratio 2.90, 95% CI 1.28 - 6.53, P=0.01, respectively).
  • CONCLUSIONS: This prospective multicenter blood biomarker validation study demonstrates that multimarker qRT-PCR analysis of CTC has significant clinical utility as a prognostic factor of disease outcome at pretreatment, and as a treatment monitoring prognostic factor in stage IV melanoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962113.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Pishvaian MJ, Marshall JL, Hwang JJ, Malik S, He AR, Deeken JF, Kelso CB, Cotarla I, Berger MS: A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. J Clin Oncol; 2009 May 20;27(15_suppl):3581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion.
  • METHODS: GMX1777 was administered at ascending doses as a 24 hour IV infusion q21 days to successive cohorts of patients with advanced malignancies.
  • Two patients had stable disease for > 4 cycles (6 & 4 mos), and 3 additional patients had SD for ≥ 3 mos.
  • CONCLUSIONS: The MTD for GMX1777 administered as a 24 hour infusion q21 days is 140 mg/m<sup>2</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kiel KD, Refaat T, Navanandan N, Sathiaseelan V: Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Median and mean FU of alive patients was 20 and 32 mos, respectively.
  • Disease volume was microscopic in 11%, less than 3 cm in 11%, and greater than in 78%.
  • CR was seen in 52% and CR/PR in 79% in pts with measurable tumor.
  • Type (primary vs recurrent), location (breast/chest wall/node), extent of disease (3 cm), or prior RT were not associated with LC.
  • All pts with microscopic disease are controlled.
  • 16 pts (12%) are NED (mean 32 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ahlgren P, Thirlwell M, O'Regan R, Mormont C, Levesque L, Gaspo R, Woloj M, Bello A, Martell B, Leyland-Jones B: An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):e12019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combining agents that target different signaling pathways may have additive/synergistic activity; combining the AI letrozole with the anti-VEGF agent bevacizumab prolonged progression-free survival to >14 mos as 1st-line therapy for HR+ MBC (Dickler et al. 2008).
  • An open-label, phase I, dose-finding study of first-line SU + E was conducted in HR+ MBC pts.
  • One death occurred on study (non treatment-related Enterobacter sepsis).
  • CONCLUSIONS: These data indicate that SU + E was tolerable with manageable toxicities, with increases in PK parameters and a similar AE profile to that of either single agent alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964247.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE: Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC).
  • The primary endpoint is PFS at 1 year.
  • RESULTS: Thus far, 31 eligible PS 0-1 pts have been accrued (med age 62 yrs, range 41-74, 19 non- squamous, 12 SQ, 63% IIIA, 37% IIIB).
  • One gr 5 late (> 2 mos after treatment) PH occurred in a SQ pt.
  • CONCLUSIONS: Preliminarily, we conclude that 1) Incorporation of B and E into this treatment paradigm appears feasible, 2) Esophagitis remains the primary toxicity, 3) Phase II accrual continues but early analysis of survival appears promising.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963295.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH: Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. J Clin Oncol; 2009 May 20;27(15_suppl):8042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.
  • Administration of B is thought to decrease nitrous oxide synthesis and lead to HTN, one of the known toxicities associated with PCB on E4599.
  • This side effect may be a physiological sign that the VEGF pathway is more actively being blocked and indicate differential outcomes between hypertensive and non-hypertensive pts.
  • Baseline characteristics of the HTN cohort were similar to those in the non-HTN cohort except for a higher proportion of PS 0 pts (70% vs. 38%, p=0.001) and females (67% vs. 48%, p=0.05).
  • Median follow-up was 54.8 mos.
  • The 6-month cumulative incidence of HTN adjusting for death as a competing risk was 6.2% (95% CI: 3.9-8.6%).
  • Proportional hazards models for OS and PFS adjusting for HTN as a time-varying covariate resulted in an OS HR=0.64 (0.43-0.96, p=0.03) and PFS HR=0.83 (0.57-1.20, p=0.32).
  • The same modeling adjusting for high BP (>150/100) as a time-varying covariate resulted in OS HR=0.60 (0.44-0.82, p=0.002) and PFS HR=0.71 (0.54-0.95, p=0.02).
  • Results for high BP remained statistically significant after adjusting for sex, PS, histology, adrenal, liver and bone mets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Naik SG, Negrin R, Laport G, Miklos D, Shizuru J, Arai S, Blume K, Wong R, Lowsky R, Johnston L: Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies.
  • : 7033 Patients (pts) with high risk (HR) or advanced myeloid malignancies have limited effective treatment options.
  • All pts were treated with a uniform preparatory regimen: busulfan 16.0 mg/kg (d-8 to-5), etoposide 60mg/kg (d-4), cyclophosphamide 60mg/kg (d-2), and graft-versus-host-disease (GVHD) prophylaxis of cyclosporine and prednisone.
  • Disease status at transplantation was induction failure (IF) acute myeloid leukemia (AML) (n = 10), HR AML in 1st complete remission (CR1) n = 11, in CR2 (n = 5), in CR3 (n = 2), relapsed refractory (RR) AML (n = 14), chronic myeloid leukemia (CML) in second chronic phase (n = 6), blast crisis (n = 2), myelofibrosis (n = 6), myeloproliferative disorders (n = 2), and MDS (n = 38).
  • Thirty-six % (n = 35) of pts received bone marrow while 64 % (n = 61) received G-CSF mobilized peripheral blood mononuclear cells (PBMC).
  • With a median follow up of 5.6 yrs (1.6-14.6 yrs) actuarial 5-year overall survival (OS) was 32% (95% CI 22-42%) and 5-year probability for freedom from progression (FFP) was 64% (95% CI 52%-76%).
  • Non-relapse mortality (NRM) was 29 % (95% CI 20%5-38%) at day 100 and 39% (95% CI 29%-49%) at one yr.
  • Cumulative incidence of acute (grade 3-4) and chronic GVHD was 28% (95% CI 19%-37%) and 38% (95% CI 24%-52%), respectively.
  • These results confirm that pts with high-risk or advanced myeloid malignancies can achieve long-term survival following myeloablative allogeneic HCT with aggressive conditioning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, Vukelja S, Agresta S, Klencke B, Birkner M, Rugo H: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. J Clin Oncol; 2009 May 20;27(15_suppl):1017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1017 Background: T-DM1 is an ADC that combines the biological activity of trastuzumab (T) with targeted delivery of a potent antimicrotubule agent, DM1, to HER2-expressing cancer cells.
  • The confirmed objective response rate (ORR) for the 9 pts with measurable disease treated at the MTD was 44%.
  • Primary objectives were assessment of ORR and of safety and tolerability.
  • RESULTS: As of the August 29, 2008, data-cut, 112 patients had enrolled, with baseline median age 54.5 (range 33-82); ECOG PS 2 or 3, 80%; 68.7% with > 3 sites of metastatic disease; median 3 (range 1-14) prior chemotherapy agents for metastatic disease, median 76.3 weeks prior T, and 55.4% with previous lapatinib.
  • With a median follow-up of 4.4 mos, there were 42 (39.3%) ORs (CR or PR), 29 (27.1%) of which have been confirmed by follow-up (F/U) imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960734.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • In patients suffering from relapsed GBM, mOS was 7.4 months, in patients suffering from relapsed AA, mOS was 9.25 months.
  • G207/Irradiation re-treatment was possible and induced anew clinical responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Morris RT, Cohn DE, Fowler J, Solomon LA, Vay A, Seward S, Heilbrun L, Smith D, Munkarah AR: Combined weekly docetaxel (D) and gemcitabine (G) for relapsed ovarian cancer (OC) and peritoneal cancer (PC): A multi-institutional phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):5565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5565 Background: Both D and G have demonstrated single-agent activity in OC and PC.
  • The purpose of this study was to prospectively evaluate the efficacy and toxicity for patients (pts) with relapsed platinum-sensitive (Plat-S) and platinum-resistant (Plat-R) OC or PC treated with combination weekly D and G.
  • D (40 mg/m2) and G (800 mg/m2) were administered on days 1 and 8 of a 21 day cycle until progression.
  • There were 2 separate 2-stage designs used, one for each stratum: Plat-R and Plat-S, separately for a total planned sample of 62 pts.
  • The primary endpoint was overall response rate (ORR).
  • Six pts (22%) achieved a complete response (CR), 10 pts (37%) achieved a partial response (PR) and one pt (4%) had stable disease.
  • Progressive disease was noted in 10 pts (37%).
  • Plat-S pts (n = 16) had a 69% ORR (CR = 31%, PR = 38%) and Plat-R pts (n = 11) had an ORR of 45% (CR = 9%, PR = 36%).
  • Median overall survival was 12.7 months (Plat-S = 14.2 mos. and Plat-R = 6.7 mos.).
  • CONCLUSIONS: Weekly D and G combination therapy demonstrates significant activity and moderate toxicity in both Plat-S and Plat-R disease.
  • This non-platinum combination deserves further evaluation and may be considered in pts with Plat-S and Plat-R OC and PC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962563.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwabi C, Gardiner E, McDermott D, Golub T, Atkins MB: A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol; 2009 May 20;27(15_suppl):9003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response.
  • : 9003 Background: HD IL-2 remains one of two FDA-approved therapies for the treatment of patients (pts) with advanced melanoma.
  • We present the clinical outcome of pts treated over a recent 2 year period with HD IL-2 at a single institution and an associated retrospective pilot study evaluating the predictive value of a novel tumor gene expression signature.
  • RESULTS: Clinical response occurred in 16 of the 49 pts (32.6%), with 5 pts (10.2%) having a CR.
  • Two other pts had stable disease > 12 mos; 3 pts who progressed after response had resection to NED.
  • 10 pts remain disease/progression free at a minimum of 16 mos following treatment.
  • CONCLUSIONS: The overall and CR rates in a contemporary series of pts with metastatic melanoma treated with HD IL-2 are twice that reported in initial studies suggesting some treatment selection on clinical grounds since the 1990s.
  • This finding requires prospective validation, but suggests immune-related gene expression might contribute to IL-2 responsiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962351.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Sperinde J, Ali S, Leitzel K, Fuchs E, Köstler WJ, Paquet A, Weidler J, Huang W, Bates M, Lipton A: Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
  • METHODS: The HERmark assay was used to measure H2T in formalin-fixed, paraffin-embedded (FFPE) primary breast tumor specimens from 99 women treated with trastuzumab for MBC.
  • At the highest levels of H2T, an abrupt decrease in the PFS rate was observed, consistent with a reduction in susceptibility to trastuzumab.
  • KM analyses demonstrated that patients who were FISH(+), H2T intermediate had a significantly longer PFS than patients who were FISH(-), H2T low (median PFS 12.6 vs. 4.5 mos; HR = 0.34; p < 0.0001).
  • Patients that were FISH(+), H2T high experienced a PFS that was no better than patients that were FISH(-), H2T low (median PFS 4.6 vs. 4.5 mos; HR = 0.87; p = 0.68).
  • MBC patients with very high levels of H2T could represent a sub-group with de novo resistance to trastuzumab who may benefit from combined therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961126.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mayer E, Baurain J, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart A: Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. J Clin Oncol; 2009 May 20;27(15_suppl):1011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequent to study initiation, dasatinib demonstrated similar efficacy with a lower incidence of key side-effects at 100 mg once daily in CML and prostate cancer.
  • METHODS: Pts with measurable disease and progression after chemotherapy and other targeted agents were treated with dasatinib on a continuous twice-daily (BID) schedule; RECIST-defined response rate was primary endpoint.
  • RESULTS: Sixty-eight pts, 24 with HER-2-amplified and 44 with HER-2-normal, ER+ and/or PR+ disease, were treated.
  • We observed 3 partial responses lasting 9, 9 and 8+ mos plus 6 stable disease ≥16 weeks (range 24-33 wks).
  • All 9 controlled tumors were ER/PR+, 2 were also HER-2-amplified; thus, disease control rate was 19% in the 47 radiographically-evaluable pts with ER/PR+ disease.
  • Median dose intensity was 136 mg/day at 70 mg BID and 175 mg/day at 100 mg BID; median duration of therapy was 1.8 mos in both dose groups.
  • Most pts (75%) discontinued for disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Wanebo HJ, Begossi G, Belliveau J, Gustafson E: Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):2555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 42 patients had advanced (irradiated) rectal cancer, 8 pts had advanced anorectal cancer, 5 patients had sarcoma.
  • Other cancers included melanoma (M 4pts), endometrial cancer (EC) 2, ovarian cancer (OC) 2, and bladder cancer (BC) 1.
  • RESULTS: Palliative IPP for advanced rectal cancer pts provided significant pain control (1-4 months) in 11 of 14 pts with narcotic resistant pain and induced tumor regression in 6 pts.
  • Preoperative perfusion in 26 advanced rectal cancer pts induced a complete path response (in pelvis) in 2 pts and significant regression in 11 pts rendering them resectable.
  • 7 had RO resection with clear margins: of the other pts 1 had a path CR negating resection, 3 refused pelvic resection, 2 became inoperable.
  • Median survival post IPP was 24 mos in 12 patients considered resectable vs. 8 mos in 12 patients considered non resectable p<0.05.
  • It was 30 months in 8 pts with advanced anorectal squamous cancer (1pt survived >90 mos), 20 months in 4 patients with endometrial/ovarian recurrence, (1 died NED >48 mos), 13 mos in 4 melanoma pts and only 5 months in 5 pts pelvic sarcoma (4-34 mos-NED).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Vij R, Wang M, Orlowski R, Stewart AK, Jagannath S, Kukreti V, Le MH, Kunkel L, Siegel D, Multiple Myeloma Research Consortium (MMRC): PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. J Clin Oncol; 2009 May 20;27(15_suppl):8537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PX-171-004 is an ongoing Phase II study evaluating safety and efficacy of CFZ in MM patients with relapsed disease after 1-3 prior therapies.
  • The primary endpoint was ORR, defined as Partial Response (PR) or better.
  • Of the BTZ-exposed cohort, 2 subjects received BTZ exclusively as a single agent, 6 had BTZ in a chemotherapy combination, and 9 received BTZ in a transplant regime.
  • In BTZ-naïve patients, CFZ achieved an ORR of 57%; median DOR of 8.6 mos (range >1.9 to >9.7 mos).
  • The median follow-up was 10 mos and the median TTP has not been reached.
  • For the BTZ- exposed group, CFZ achieved an ORR of 18%; median DOR not yet reached (>8.5 mos) (range >1 d to >8.5 mos).
  • Median follow-up and TTP were 9.2 and 8.9 mos, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Philip PA, Gupta S, Heilbrun L, Smith D, El-Rayes B, Shields A: &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):e15037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC).
  • The growing complexity of current therapies and the increasing number of agents to be tested in this disease warrants better understanding of the role of FDG-PET in earlier treatment decisions.
  • 56% and 37% of pts had partial response and stable disease (RECIST criteria), respectively.
  • Median TTP was 13.0 months (90% CI: 10.9 - 16.3 mos), with a median follow-up time for progression of 7.8 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964469.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Li W, Zhang W, Cai S, Yin J, Li J: Prognostic factors for colorectal cancer patients with pulmonary metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15107 Background: Pulmonary is the second common metastastic site of CRC with a good survival after metastasectomy, however the general situation of pulmonary metastases from CRC has received little attention, especially for unresectable ones.
  • The aim of this study was to determine factors that may influence survival and disease free interval from primary radical surgery to pulmonary metastases (DFI).
  • METHODS: From 01/2000 to 11/2008, a total of 206 pts with pulmonary metastases (colon72, rectal ca131, 3 unknown) were collected retrospectively and the clinical data were analyzed using Kaplan-Meier survival curves, univariate and multivariate analysis.
  • RESULTS: 128 pts (62.1%) had lung disease as the first metastatic site and 33 pts (26.7%) had synchronous liver involvement.
  • Median survival was 16.0 months (range 12.240-19.760) with a 18% 5-year survival.
  • Of the totally 160 patients who had synchronous pulmonary metastases after radical primary tumor surgery, the mDFI was 20 months (range 16.738-23.262) months.
  • Rectal cancer had a high chance (65%) for lung recurrence with longer DFI (21 vs 14 mo, P=0.02), but no difference of survival was shown compared to colon cancer.
  • The factors influencing the DFI of metachronous pulmonary metastases included primary tumor site, pathological morphology, tumor infiltration stage and regional lymph node stage (P<0.05).
  • There was a trend of better survival of patients receiving resection surgery after pulmonary metastases than receiving chemotherapy alone though no statistical significant was reached (mOS:34 vs 16 mo, P=0.125).
  • The invasive tumor with high stage may have a shorter disease free interval of pulmonary metastases after primary surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Tang P, Gill S, Au HJ, Chen EX, Hedley D, Leroux M, Wang L, Moore MJ: Phase II trial of erlotinib in advanced pancreatic cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):4609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benefit from erlotinib (Tarceva), an oral EGFR tyrosine kinase inhibitor has been associated with the presence of a skin rash.
  • METHODS: Erlotinib was given at an initial dose of 150 mg/day to eligible pts with locally advanced (LA) or metastatic PC who had progressed or were unable to tolerate gemcitabine-based chemotherapy.
  • The primary endpoint of this two- stage phase II trial was prolonged disease control (PR + SD > 8 wks) with a rate of >20% assumed to be significant .
  • RESULTS: Fifty pts were accrued (median age 61, M:F = 25:25, ECOG 0:1:2 = 5:41:4, LA:Metastatic = 5:45, prior gemcitabine none:adjuvant:palliative = 2:16:35).
  • Prolonged disease control (SD > 8 wks) was observed in 10/40 evaluable pts, 0.25 (95% CI: 0.12-0.38), which met the primary study endpoint.
  • Median TTP was 1.6 mo (95% CI:1.6-2.1), mOS 4.1 mo (95% CI:3.2-7.3), and 6 mo OS rate was 39% (95%CI: 24-61%).
  • CONCLUSIONS: Erlotinib is associated with prolonged stable disease in a subset of pts with advanced refractory PC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Fernandes A, Faerber J, Finlay J, Shen J, Lin L, Evans T, Stevenson J, Langer C, Glatstein E, Hahn S, Rengan R: Clinical outcomes of elective nodal irradiation (ENI) compared with involved field radiotherapy (IFRT) in NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):7541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7541 Background: Local failure rates in patients treated with definitive radiotherapy for non-small cell lung cancer (NSCLC) remain high.
  • IFRT allows higher radiation doses to the primary tumor with the goal of reducing local failure rates while minimizing toxicity.
  • The median follow-up time was 8.4 mos (0.3-43.4) for all pts and 9.7 mos (1.5-40.1) for survivors.
  • CONCLUSIONS: Our data suggest that IFRT does not result in increased nodal failures or decreased survival compared to ENI, and may result in increased local control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Boccardo F: An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts). J Clin Oncol; 2009 May 20;27(15_suppl):e16080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However possible interferences between B and T,especially after prolonged administration, remain a matter of concern.In order to reduce the exposure to T,we considered the putative advantages of a weekly administration based on T effects being dose -dependent and on drug long half-life.
  • METHODS: This was a non inferiority trial.
  • Gy (primary endpoint), breast pain (bp), serum PSA levels and sexual functioning scores were evaluated.
  • RESULTS: At a median F.U. of 24.2 mos (95% CI: 23.7 -24.6) gy developed in 31.7% of pts in d group and in 74.4% of pts in wk group (p < 0.000).
  • There were no major differences among treat. schedules relative to sexual functioning scores, PSA behaviour and disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963100.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Yau CC, Chen PJ, Curtis CM, Murphy PS, Suttle AB, Arumugham T, Hodge JP, Dar MM, Poon R: A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):3561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 27 Asian pts have been enrolled at QD doses of 200 (4 pts), 400 (10), 600 (8), 800 (5): median (range) age = 61 (38-76); M/F = 85%/15%; ECOG 0/1 = 59%/41%; 81% with metastatic disease; 67% with Stage IV; 22% with prior systemic therapy, 26% with prior TACE.
  • Best response was PR in 2 pts (7%; 1 at 800mg, 1 at 600 mg) and SD > 4 mos in 11 pts (41%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Piovesan C, Fumagalli E, Coco P, Palassini E, Dileo P, Morosi C, Gronchi A, Casali P: Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore used the mTOR inhibitor sirolimus in three pts with a PDGFRA-D842V metastatic GIST.
  • RESULTS: Two pts had a Choi's response 6 and 3 mos, respectively, after starting the combination.
  • Disease was stable at 2 mos, although clinical improvement was noticed, and therapy is ongoing.
  • The first pt underwent surgery of residual peritoneal disease after 13 mos, and is now continuing therapy being surgically NED.
  • The other pt had a tumor progression after 9 mos from starting therapy and 6 mos from tumor response (with a negative PET scan).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963816.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Kolev V, Mironov S, Mironov O, Moskowitz C, Ishill NM, Gardner GJ, Levine DA, Hricak H, Barakat RR, Chi DS: The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer.
  • METHODS: We performed a retrospective chart review of all patients (pts) with FIGO stage III and IV EOC who had preoperative CT scans of the supradiaphragmatic region and primary cytoreductive surgery at our institution between 1997 and 2004.
  • RESULTS: A total of 212 eligible pts who underwent attempted primary cytoreduction followed by platinum-based systemic chemotherapy were identified for evaluation.
  • With a median follow-up time of 52 mos, there were 135 deaths and a median overall survival of 48 mos (95% CI: 44-53).
  • None of the 44 pts with adenopathy had the enlarged nodes removed at primary cytoreduction.
  • The median survival was 49 mos for pts with and 48 mos for patients without adenopathy (p = 0.46).
  • In total, 155 (73%) patients underwent optimal cytoreduction (residual disease ≤ 1 cm).
  • In the optimally cytoreduced pts, the median survival for the 125 pts without supradiaphragmatic adenopathy was 52 mos (95%CI: 45-59) compared to 51mos (95%CI: 41-58) for the 30 pts with supradiaphragmatic adenopathy (p = 0.33).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Boccardo F, Rubagotti A, Guglielmini P, Sismondi P, Farris A, Amadori D, Agostara B, Gambi A, Catalano G, Faedi M: Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After CT, tamoxifen (plus a LH-RH analog in menstruating women ) was given for 5 years to all HOR+ pts.S was the primary end-point.
  • RESULTS: At 82 mos median f-up, S and RFS did not differ significantly between groups (7-yr S: E-CMF:76%,T- EV:74%;adjust.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ: A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol; 2009 May 20;27(15_suppl):5114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this analysis was to establish a CAF signature based on a set of individual markers at BL with a significant and differential impact on the association between treatment arm and PFS.
  • Pts with high OPN benefitted more from single agent SR (7.74 vs. 3.93 mos for the combination; p = 0.007), but no differences were found for those with low OPN.
  • Lower than median on-treatment increases in sCA9 (D28, p = 0.01) and GRO-alpha (D56, p = 0.04) on SR only were also associated with a better outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Rice K, Peay K, Hudak J, Elsamanoudi S, Travis J, Lockhart R, Jennifer C, Black L, Hogue S, Brassell S: Factors for choosing prostate cancer treatment and resulting impact on health related quality of life. J Clin Oncol; 2009 May 20;27(15_suppl):9601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The instruments are the EPIC, EPIC Demographic, and the MOS Short-Form 36.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Caffo O, Fellin G, Graffer U, Mussari S, Caldara A, Murgia V, Valduga F, Tomio L, Galligioni E: Cisplatin (C) and gemcitabine (G) chemotherapy with concurrent irradiation (XRT), for the conservative treatment of invasive transitional bladder cancer (ITBC) patients: Clinical outcome and long-term follow-up in a monoinstitutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a dose finding trial, conducted in our hospital on ITBC patients using C and G with concurrent XRT, after maximum transurethral resection (TUR), the maximum tolerated dose of G was 400 mg/sqm (IJROBP 2003).
  • We are presenting the long-term clinical outcome of the 16 patients involved in the dose-finding trial, together with that of the 9 pts enrolled in the phase II study.
  • In dose finding study G was given weekly from 200 to 500 mg/sqm: since unacceptable toxicity was observed in 2 cases (one death for toxicity) at the higher dose level, the recommended G dose for phase II trial was 400 mg/sqm on day 1,8 q 21 for 2 courses together with C and XRT.
  • A cystoscopic re-evaluation was scheduled 6-8 weeks after treatment.
  • RESULTS: Except the pt died during treatment for toxicity, all the remaining 24 pts were microscopically disease free at cystoscopic re-evaluation.
  • Seven local and 2 distant relapses have been observed so far, at a median follow-up of 66 mos.
  • Presently, 16 pts (67%) is alive and disease-free, with 1 patient died for lung cancer.
  • All pts alive have retained their bladder, with a normal organ function, in absence of any relevant long-term toxicity.
  • Considering the 100% of complete response observed, this combination could be of interest to explore a possible enhancement of the disease control of C plus XRT, that is today the treatment of choice in the conservative therapy of ITBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963102.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Vogelzang NJ, Hutson TE, Samlowski W, Somer B, Richey S, Alemany C, Loesch D, Richards P, Gardner L, Sportelli P: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):5034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.
  • In a prior trial, 15 RCC patients (pts) were enrolled in a randomized dose finding study, 9 were evaluable for response and 3 (33%) had a partial response (PR).
  • Thus phase II trials were begun for pts who had been treated with one prior VEGFr inhibitor (Group A) or with a prior VEGFr inhibitor and prior mTOR inhibitor (Group B).
  • METHODS: To measure the objective response rate (RECIST) and PFS to single agent perifosine (100 mg qhs with food) after 3 mos of Rx; Prior Rx with vaccine therapy, bevacizumab and/or cytokines was permitted.
  • Normal organ/marrow function was required.
  • Median age 64 (range 46-80) and 36 were male; Median prior Rx was 2 (range 1 - 5); Clear cell = 37, non clear cell = 6, data n/a = 3.
  • CONCLUSIONS: Perifosine, similar to mTOR inhibitors, appears to have clinical benefit in mRCC as reflected by the PR rate and a 15 wk median overall PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, Saijo Y, Gemma A, Morita S, Hagiwara K, Nukiwa T: First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol; 2009 May 20;27(15_suppl):8016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group.
  • Pts having sensitive EGFR mutations, measurable site(s), ECOG PS 0-1, age of 20-75 years, and no prior chemotherapy were randomized (1:1 ratio; balanced for institution, sex, and stage) to receive Arm A: gefitinb (250 mg/ day) orally, or Arms B: CBDCA AUC 6 and TXL 200mg/m2 in 21-day cycles until disease progression.
  • The primary endpoint was PFS, and the sample size was calculated to be 320 in total (alpha=5%, power=80%) to confirm the superiority of Arm A (hazard ratio = 0.69).
  • Their characteristics were well balanced between arms: median age=65 years; 64% female; 77% Stage IV; 93% adenocarcinoma, 61% non-smoker.
  • There were several differences in toxicities between Arm A and Arm B (grade 4 neutropenia: 1% vs. 29%, grade 3-4 liver dysfunction: 24% vs. 1%, grade 3 neuropathy: 0% vs. 5%, respectively, p<0.01).
  • Furthermore, there were no interstitial lung disease and no toxic deaths in both arms.
  • Analyzing both arms together, preliminary response rate and PFS of the 155 pts were 53.7% and 6.5 mos, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Krop IE, Burris HA, Rugo H, O'Shaughnessy J, Vogel CL, Amler L, Strauss A, Wong EK, Klencke B, Pippen J: Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). J Clin Oncol; 2009 May 20;27(15_suppl):1003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: As of August 29, 2008, 112 pts had enrolled; 107 were efficacy-evaluable pts with median 4.4 mos follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960714.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Vickers MM, Choueiri TK, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY: Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? J Clin Oncol; 2009 May 20;27(15_suppl):5098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 645 patients with mRCC who received initial VEGF-targeted therapy were identified (sunitinib, sorafenib or bevacizumab) and had a median follow-up of 25 mos.
  • Of these, 218 patients (34%) received second-line targeted therapy: the median age was 62 yrs (range, 41-87), median KPS was 90%, 90% had prior nephrectomy, 3.8% had non-clear cell histology, 5.8% had brain metastases and 79% had > 1 metastatic site.
  • Patient characteristics were similar aside from more non-clear cell histology in patients receiving second-line mTOR-inhibiting agents (14% vs 3% p = 0.045).
  • The median time to treatment failure (TTF) of second-line therapy was 4.9 mos for anti-VEGF therapy and 2.5 mos for mTOR inhibitors (p = 0.014).
  • However, patient selection may account for this finding and overall survival was not significantly different.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Van Schil PE, Baas P, Gaafar R, Maat AP, van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, Van Meerbeeck J, EORTC Lung Cancer Group: Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol; 2009 May 20;27(15_suppl):7509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031).
  • : 7509 Background: MPM is a highly lethal disease and the role of EPP in the treatment of early stage, potentially resectable MPM remains controversial.
  • Non-progressing patients (pts) underwent EPP followed by PORT (54Gy, 30 fractions).
  • Primary endpoint was "success of treatment" defined as a patient receiving the full protocol treatment, still alive 90 days after end of treatment without progression and without grade (G) 3-4 toxicity.
  • R0/1/2: 30/10/3, 6 were re-operated, pT0/1/2/3/4: 2/5/19/15/4, pN0/1/2/3: 34/2/6/2, 90-day mortality: 3 pts (6.5%); in 38 pts (83%) postoperative complications occurred.
  • After median follow- up of 19.3 months (mos) median overall survival time was 18.4 mos (95% CI 14.8-NR) and median progression-free survival was 13.9 mos (95% CI 10.9-17.1).
  • Only 24 pts (42%) met the definition of success (one-sided 90% CI 0.36-1.00).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963479.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials H, Mendelson D, Shannon P, Gordon M: A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The maximum tolerated dose (MTD) was expanded to 10 pts each with colorectal (CRC), melanoma, papillary thyroid (PTC) and NSCLC.
  • One pt with an ocular melanoma demonstrated a cPR of 4 mos duration.
  • Twelve pts had SD (3 -17+ mos), including 2 with I<sup>131</sup>-refractory PTC harboring BRAF V600E mutations (15+ and 17+ mos).
  • At the MTD, paired biopsies from 4 pts (3 melanoma, 1 NSCLC) show an average 72 % decrease in pMEK, 68 % decrease in pERK, 24 % decrease in Ki67 (proliferation) and 64 % increase in TUNEL (apoptosis).
  • Three of 6 evaluable pts in the MTD cohort show SD at first assessment, including 1 melanoma pt with a NRAS Q61R mutation who showed a 20% decrease in target lesions.
  • One cPR occurred in an ocular melanoma subject, and clinical benefit (PR or SD) occurred in 43% (13/30) of pts in the dose-escalation phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961303.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Oettle H, Hilbig A, Seufferlein T, Schmid RM, Luger T, von Wichert G, Schmaus S, Heinrichs H, Schlingensiepen K: Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma.
  • METHODS: 33 patients with advanced pancreatic carcinoma (stage IVA/IVB) (N=23), malignant melanoma (stage III/IV) (N=5) or colorectal carcinoma (stage III/IV) (N=5) were treated with trabedersen as 2nd-4th-line treatment.
  • PRIMARY STUDY OBJECTIVE: maximum tolerated dose (MTD); secondary objectives: safety and tolerability, pharmacokinetics and antitumor activity.
  • Of the 5 melanoma patients one from the 1st schedule showed stable disease and lived for 13.8 months; 3 patients from the 2nd schedule are still alive.
  • Median overall survival (mOS) for pancreatic carcinoma patients in the 1st schedule was 6.8 months.
  • Current mOS for pancreatic carcinoma patients in cohort 1 (N=5) of the 2nd schedule is 13.2 months; 2 of these patients are alive, one with stable disease 14.8 months after begin of trabedersen treatment.
  • A randomized, active-controlled phase II study compared to standard therapy in patients with pancreatic carcinoma is in preparation; another one in malignant melanoma is being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA: Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):8065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible pts were chemotherapy-naïve women, stage IIIB/ IV, PS 0-2, adenocarcinoma, and w/ available tissue for analysis of EGFR mutation status.
  • Pts received erlotinib 150 mg PO daily until disease progression or unacceptable toxicity.
  • Primary endpoint was response rate (RR).
  • EFFICACY: Response (n=84): 0 CR, 27 PR (RR 32%), 27 SD, 23 PD.
  • 7 pts not evaluable (5 tox, 1 non-progression death, 1 withdrawn consent).
  • Median TTP was 5.6 months (95% CI 4.1-7.4 mos), and median OS was 22.7 months (95% CI 15.8 - 26.0 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962638.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Diaz Romero C, Olvera N, Martínez H, Mtz Cedillo J, Cuellar M, Morales R, Álvarez M, Segura B, De la Garza J, Aguilar P: Paclitaxel plus carboplatin (PC) in patients with metastatic melanoma (MM): Experience in a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):e20019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel plus carboplatin (PC) in patients with metastatic melanoma (MM): Experience in a single institution.
  • : e20019 Background: The number of agents active in patients with metastatic melanoma is limited and cure is not an objective for treatment at this stage, so that clinical benefit in these patients is the most important.
  • The regimen was weekly paclitaxel (at a dose of 80 mg/m2) received on days 1, 8, and 15 of a 21-day cycle and carboplatin (AUC 5) on day 1.
  • Objective partial response were obtained in 4 patients (25%); 8 stable disease (50%) at least four months.
  • Progression disease was in 4 patients (25%).
  • The median time to disease progression for the entire group was 4.2 months (range, 1-11 mos), with a median overall survival of 8.1 months (range, 5.6-10.5 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962551.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Campos LT, Nemunaitis J, Stephenson J, Richards D, Barve M, Gardner L, Niecestro R, Sportelli P: Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a phase III randomized study, sorafenib demonstrated a 2% partial response (PR) rate with a median time to symptomatic progression of 4.1 months (mos) and radiologic progression of 5.5 mos, however patients (pts) had not received prior systemic treatment.
  • Peri was evaluated in a phase II multi-disease trial where 558 pts were randomized to daily vs. weekly schedules of Peri (50/100 mg daily or 900/1,200 mg weekly) with 42 of the pts having HCC.
  • Normal organ / marrow function required.
  • Primary outcome analyses included median time to progression (TTP) and disease control rate (DCR; CR+PR+SD > 12 weeks).
  • One patient achieved a PR (3%) and 15 (47%) had stable disease > 12 weeks; overall DCR of 50%.
  • As of 12/08, one patient remains active at 12 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962225.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Vidaurre T, Wilkerson J, Bates SE, Simon R, Fojo AT: Value of stable disease (SD) in drug development of targeted therapies (TGT). J Clin Oncol; 2009 May 20;27(15_suppl):2509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of stable disease (SD) in drug development of targeted therapies (TGT).
  • Aware the acceptance of SD as a measure of activity led to its being increasingly reported with traditional cytotoxic agents (CTX), we set about to methodically compare the occurrence of SD in phase II trials of TGT and CTX.
  • Thirty-eight properties including CR, PR, SD, PFS, and OS were recorded for each study.
  • For CTX vs. TGT, the median numbers of pts/study was 47.1 vs. 51.9; median PFS, 5.55 vs. 4.54 mos; and median OS, 12.55 vs. 12.88 mos.
  • The overall response rate (CR + PR) was higher with CTX than with TGT (29.4% vs. 13.3%) and demonstrated a strong correlation (p<0.0001) of uncertain importance with PFS and OS for all therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961963.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • METHODS: Pts ≥ 21 years (yrs) with primary refractory or relapsed ALL, NYHA class < 3, and a cardiac ejection fraction ≥ 45% were eligible.
  • Seven (23%) pts were primary refractory.
  • Among the remainder, preceding median remission duration was 8.6 mos (1-39 mos).
  • Evaluable for response were 28 pts: 3 CR (one pt in cohort 1) and 1 marrow CR (OR 14%).
  • One pt had Ph+ ALL, and one was primary refractory to HCVAD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15114 Background: In a previous study, IFL was used in patients (pt) with untreated metastatic colon cancer and a median overall survival (MOS) of 31 months (m).
  • The primary end-point is MOS Methods: Each cycle involved 6 weeks (wks) of treatment.
  • The treatment cycle consisted of a 90 minute infusion of I (110 mg/m<sup>2</sup>), followed by a 24 hour infusion of F (120mg/kg) and L (500 mg/m<sup>2</sup>) on wks 1, 2, 4, 5.
  • Quality of life data and thymidylate synthase expression in peripheral blood mononuclear cells was monitored Results: 22 pt with a median age of 57 (38-82), 11 males and 11 females were enrolled.
  • 8 pt (36%) had bilobar liver disease and involvement of 1 other organ, 6 pt (27%) had bilobar liver disease with involvement of ≥ 2 other organs; 5 pt (23.5%) had bilobar liver disease; 2 pt (9%) had abdominal carcinomatosis; 1 pt (4.5 %) had involvement in one liver lobe.
  • Grade (Gr) 4 toxicity: pulmonary embolus 1 pt (5%) incidental CT finding.
  • 5 pt have died due to progression of disease.
  • The estimated median time to progression was 13 m with corresponding lower 95% confidence bound of 8.4 m.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Franklin WA, Gandara DR, Kim ES, Herbst RS, Moon J, Redman MW, Olsen C, Hirsch FR, Mack P, Kelly K: SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):11076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC).
  • There was a trend for overall survival and EGFR level at each cutpoint in S0536 but the results did not achieve statistical significance (15 vs 11 mos, p=0.14; 15 vs 11 mos, p=0.20 and 14 mos vs not reached, p=0.10, respectively).
  • Vimentin (6 positive pts) was associated with a shorter PFS, HR=2.60 (1.10-6.14), p=0.03.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J: ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. J Clin Oncol; 2009 May 20;27(15_suppl):5038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated Dox/Gem in these pts with locally advanced or metastatic disease to confirm previous activity of this regimen in a single institution trial.
  • METHODS: Pts received Dox 50mg/m<sup>2</sup> IV push and Gem 1500mg/m<sup>2</sup> IV over 30 minutes every 2 weeks (with G-CSF 5 mcg/kg/d days 2 or 3 to 10 or pegfilgrastim 6 mg day 2) until disease progression or unacceptable toxicity.
  • Pts were mostly male (81%), with cT3/T4 (68%), node negative (61%), M1 (58%) disease at diagnosis and ECOG PS 0-1.
  • 9 patients had stable disease.
  • Two pts are alive without progression (1 with a PFS of 2.5 years), 1 is alive with progression, and 35 patients have died.
  • Median PFS is 3.5 months (95% CI 2.8-5.2 mos).
  • Median OS is 8.8 mos (6.1-11.1 mos).
  • CONCLUSIONS: Dox/Gem met efficacy criteria in RCC with sarcomatoid features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Vishnu P, Jasti P, Ding L, Heilbrun LK, Venkatramanamoorthy R, LoRusso PM, Heath EI: Retrospective study of phase I clinical trials participation in patients at least 65 years of age at Karmanos Cancer Institute (KCI), Wayne State University, Detroit, Michigan. J Clin Oncol; 2009 May 20;27(15_suppl):e20626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to describe the demographics, treatment, toxicity, and overall survival (OS) of all patients ≥ 65 years who presented to the Phase I clinical trials service at KCI between 1995-2005.
  • RESULTS: 216 patients met the study criteria.
  • 66% of patients had a history of cardiovascular disease but renal, liver, hematological diseases were found in less than 7% of patients at baseline.
  • The median OS for PC, PE, and PT was 3.9 mos, 2.2 mos, and 8.4 mos, respectively (p < 0.001 between any pair).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961597.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Gutierrez M, Murgo AJ, Allen D, Turkbey I, Gardner ER, Trepel J, Chen H, Giaccone G, Doroshow JH, Kummar S: Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. J Clin Oncol; 2009 May 20;27(15_suppl):3522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIAGNOSIS: pancreatic-1, NSCLC-1, colorectal-3, peritoneal mesothelioma-1, melanoma-1, NHL-1, jejunal adenocarcinoma (JAC)-1.
  • Partial Response (PR) was achieved in 2 pts (pancreatic 14 mos + and JAC 6 mos); disease stabilization in 5 pts (4 mos +).
  • CONCLUSIONS: We decided not to escalate beyond DL 2 due to the gr 2-3 toxicities observed with chronic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts (N = 400 planned) with clear cell advanced RCC and measurable disease with no prior treatment or 1 prior cytokine-based treatment, were stratified and randomized (2:1) to pazopanib 800 mg QD or placebo.
  • The primary endpoint was progression-free survival (PFS).
  • The study had ≥ 90% power to detect an 80% improvement in PFS and a 50% improvement in OS, by stratified log-rank tests with α = 0.025 one-sided.
  • Pts received continuous treatment until disease progression (PD), death or unacceptable toxicity.
  • PFS was significantly prolonged with pazopanib in the overall study population (9.2 vs 4.2 mos; HR: 0.46; 95% CI: 0.34, 0.62; p < 0.0000001), in treatment naïve pts (11.1 vs 2.8 mos; HR: 0.40; 95% CI: 0.27, 0.60; p < 0.0000001), and in cytokine-pretreated pts (7.4 vs 4.2 mos; HR: 0.54; 95% CI: 0.35, 0.84; p < 0.001).
  • Median duration of exposure was 7.4 mos (pazopanib) and 3.8 mos (placebo).
  • The most common laboratory abnormality was ALT elevation (53%; 10% Gr 3; 2% Gr 4).
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.
  • Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Conkling P, Spigel D, McNally R, Renschler M, Oliver J: Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update. J Clin Oncol; 2009 May 20;27(15_suppl):8103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.
  • Patients (pts) with SCLC, who are refractory to first-line chemotherapy or progress within 3 months (mos) of treatment completion, are less likely to respond to additional chemotherapy and have an expected median survival of 3-5 mos.
  • The primary endpoint was response rate (ORR, by RECIST), with a goal to demonstrate an ORR ≥18% (point estimate).
  • RESULTS: In all, 75 pts were enrolled with a median age of 63 years (range 43-88), 52% female, 17% PS 2.
  • Response to 1<sup>st</sup>-line therapy was 5% complete remission (CR), 36% partial remission (PR) and 28% PD.
  • Median time from completion of 1<sup>st</sup>-line therapy to PD was 1.3 mos.
  • The primary endpoint was met with an ORR of 21% (16/75, 95% confidence interval [CI] 13.6% - 31.9%), including CR in 1 pt (1%) and PR in 15 pts (20%).
  • Stable disease was achieved in 40% of pts.
  • Median OS was 6.0 mos (95% CI 4.8-7.1 mos).
  • Median PFS was 3.2 mos (95% CI 2.4-4.0 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Battaglia M, Gernone A: Long-term use of sorafenib (SOR) in metastatic renal cell carcinoma (mRCC) previously treated with systemic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16123 Background: The recent development of new targeted agents for the treatment of advanced RCC has definitely changed the approach and the outcome of this disease.
  • They were18 males and 4 females, with a median age 67 years, an ECOG PS 0-2, and the majority (96%) had undergone prior nephrectomy.
  • Patients were assessed for activity every three months (mos.) by CT.
  • The primary endpoints were response rate (RR) evaluated by RECIST criteria and time to progression (TTP).
  • RESULTS: To date, 20 pts are evaluable for response: of them, 13 (59%) achieved a partial response (PR) after 3 mos. of therapy whose median duration was 13 mos. (range, 7-18), while 7 (31%) remained with stable disease (SD) with a median length of 14 mos. (range, 5-17).
  • Among those who progressed (2 pts), the median time to disease progression was 7 mos.
  • At a median length of time of 15 mos., 18 pts. are continuing the therapy with SOR and in all of them the benefit achieved remained unchanged.
  • However, notwithstanding the rather small sample size of pts., the overall clinical benefit rate (PR+SD) turned out particularly high (> 90%): chiefly, the evidence of a long lasting disease control both for patients achieving partial response and for those with stable disease makes SOR a very useful treatment for patients with mRCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Le Coutre PD, Giles F, Hochhaus A, Apperley JF, Ossenkoppele G, Haque A, Gallagher NJ, Baccarani M, Cortes J, Kantarjian H: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
  • : 7057 Background: Nilotinib is a potent and highly selective BCR-ABL inhibitor approved for the treatment of Ph+ CML patients (pts) in chronic phase or AP who are resistant or intolerant to prior therapy including IM.
  • METHODS: Primary endpoint was confirmed hematologic response (HR).
  • RESULTS: 137 CML-AP pts (80% IM-resistant; 20% IM-intolerant with resistance) with minimum follow-up of 11 months (mos) (median age, 57 years; median duration of prior IM treatment, 28 mos) were included.
  • Responses were rapid, with a median time to first HR of 1 mo.
  • HRs were durable at 24 mos with 54% of pts maintaining their response.
  • Cytogenetic responses were also durable with 70% of pts maintaining MCyR at 24 mos; 83% of pts maintained CCyR at 12 mos.
  • Estimated OS at 24 mos was 67%.
  • Grade 3/4 non-hematologic AEs were rare (< 1%) and included nausea, fatigue, and diarrhea.
  • CONCLUSIONS: These long-term follow-up results confirm that nilotinib induces rapid and durable responses in CML-AP pts who failed prior IM due to intolerance or resistance, with a favorable risk/benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Landau HJ, Hoffman J, Hassoun H, Elizabeth H, Riedel E, Nimer SD, Cohen A, Comenzo RL: Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL). J Clin Oncol; 2009 May 20;27(15_suppl):8540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8540 Background: Melphalan (MEL) and autologous stem cell transplant (SCT) induces both hematologic and clinical remissions in AL, and prolongs overall survival (OS) when complete hematologic remissions (CR) are achieved.
  • We have reported improved responses (including 39% CR) at 12 mos post-SCT using risk-adapted MEL followed by adjuvant dexamethasone (Dex) and thalidomide (Thal) (BJH 2007;139:224).
  • Response was assessed at 2-3 months (mos) and 12 mos following SCT.
  • Pts who did not achieve hematologic CR at 2-3 mos post-SCT received adjuvant therapy with Bort and Dex for up to 6 cycles (26 weeks).
  • The impact of heart disease on OS was determined using the log-rank test; BNP and Trop-I were correlated with OS using the Cox proportional hazards model.
  • Of 21 pts evaluable post-SCT, 5 achieved CR and 16<CR, 15 receiving adjuvant therapy.
  • At 12 mos post-SCT, 12 pts are evaluable.
  • In these 12 pts, the ORR was 92% (11/12) with 67% (8/12) achieving CR.
  • CONCLUSIONS: Adjuvant Bort and Dex effectively eradicates clonal plasma cell disease in pts with AL following SCT and results in an unprecedented CR rate at 12 mos post-SCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Randall-Whitis L, Burger RA, Sill M, Monk BJ, Buening Ccrc B, Sorosky JI: Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e16505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial.
  • The primary objective of this study was to determine the proportion of pts treated with bevacizumab on a phase II clinical trial with stable disease by RECIST who demonstrated disease progression (pgrn) as assessed by modified GCIG CA125 criteria.
  • Primary endpoints of the clinical trial were progression-free (PF) survival at 6 months and response assessed by RECIST criteria.
  • Pts were removed from therapy/evaluation for disease prgn by RECIST, toxicity, or by subject request.
  • RESULTS: The median PFS by RECIST was 4.7 mos.
  • Of those patients who had prgn by CA125, the median residual time to prgn by RECIST was 1.4 mos.
  • In all, twenty-five (40.3%) pts survived PF for 6 mos. by RECIST and 16 (25.8%) by CA125.
  • Ten pts who survived PF for at least 6 mos. by RECIST indicated treatment failure before 6 mos. by CA125, or 40% of the 25 positive outcomes.
  • Eight pts continued to receive treatment for at least 4 mos. after prgn by CA125, with one continuing therapy for more than 3 years.
  • CONCLUSIONS: Serum CA125 levels were a useful marker of progression in some pts treated on this trial; however, some pts received clinical benefit from continued therapy in spite of indications of disease prgn by CA125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960764.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Cortes JE, Khoury HJ, Corm S, Nicolini F, Schenk T, Jones D, Hochhaus A, Craig AR, Humphriss E, Kantarjian H, Omacetaxine 202 Study Group: Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial. J Clin Oncol; 2009 May 20;27(15_suppl):7008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.
  • : 7008 Background: Omacetaxine (OM), a first-in-class cetaxine shows clinical activity against Ph+ CML with a mechanism independent of tyrosine kinase inhibition.
  • RESULTS: 66 pts (39 chronic [CP], 16 accelerated [AP] and 11 blast phase [BP]) have been enrolled.
  • Median disease duration is 58 mos.
  • OM is well tolerated with transient myelosuppression as the primary toxicity.
  • Grade 3/4 non-hematologic events are diarrhea (2%) and fatigue (4%).
  • CONCLUSIONS: Omacetaxine in T315I+ CML Pts results in de-selection of the T315I clone and induces hematologic and cytogenetic responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Hartmann JT, Aschoff P, Dittmann H, Lichy M, Mayer F, Reischl G, von Weyhern C, Kanz L, Claussen CD, Pfannenberg C: The value of PET/CT with 18F-FLT and 18F-FDG in the management of metastatic germ cell tumors (GCT): A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e16142

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were validated by histopathology of resected residual masses after CTh in 7 pts or by clinical follow-up for at least 6 mos in 4 pts.
  • Presence of necrosis was judged as responder, as well as CR/PRm- within a minimum progression-free interval (PFI) of 6 mos.
  • RESULTS: 8 out of 11 pts had a PFI > 6 mos (range, 206-1337 days).
  • SUVavg decrease in early response FDG monitoring was 64% in responders and 60% in non-responders (p = 0.8), as well as 57% vs. 48% for FLT (p = 0.5), respectively, and 85% vs. 72% (FDG, p = 0.1) and 67% vs. 65% (FLT, p = 0.8) in the final monitoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Mancuso AP, Donato De Paola E, Catalano A, Calabrò F, Messina C, Zivi A, Cerbone L, Vigna L, Caristo R, Sternberg CN: Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e16027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts with no progressive disease (evaluated at 12 weeks) continued to receive Sorafenib at the standard dose, while progressive pts received an increasing dose (600 mg BID) with early disease restaging after 4 weeks.
  • RESULTS: 18 pts were entered; baseline characteristics: PS 0-1: 94%; median age 62 years (41-82); nephrectomy: 100%; surgery for metastatic disease: 28%, clear-cell 78%, papillary-cell 16%, sarcomatoid 6%.
  • Overall, 72% of pts had disease control without significant correlations between response to prior therapy and hypertension.
  • 14 pts had progression free survival (PFS) of 4.3 months (mos).
  • 4 pts are still in treatment with a median PFS > 8 mos.
  • Of 6 pts in which the dose was escalated, 3 benefitted with a PFS of > 3 mos.
  • Other hematological and non-hematological toxicities were g1 with a frequency < 15%.
  • In progressive patients, treatment with a higher dose could be a valid option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Cerbone L, Van Ginderdeuren R, Van den Oord J, Fieuws S, Spileers W, Van Eenoo L, Wozniak A, Sternberg CN, Schöffski P: Clinical presentation, pathological features, and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease. J Clin Oncol; 2009 May 20;27(15_suppl):e20005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, pathological features, and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease.
  • : e20005 Background: Uveal melanoma (UM) is a rare disease characterized by an unpredictable course and variable outcome ranging from cure by local treatment to the occurrence of untreatable metastasis.
  • RESULTS: The med. age at diagnosis of UM was 58 yrs (range 30-94).
  • MUM was more common in women (F:M ratio 48:28) and independent from the side of the primary tumor (left vs. right eye).
  • Synchronous metastasis was found in 9% of cases, all others had metachronous disease after a med. interval of 40 mos (range, 7-420).
  • Statistical analysis failed to identify predisposing factors for MUM with the exception of a significant negative correlation between age at diagnosis of UM and time until metastatic disease (Spearman ρ = -0.4, p<0.001).
  • The most frequent sites were liver (96%), lung (23%), subcutaneous (13%), bone (11%) and brain (3%).The med.
  • OS from diagnosis of UM was 46 mos (range, 2-182), and 4,5 mos after diagnosis of metastasis (range, 1-128).
  • CONCLUSIONS: In this orphan disease with female predominance metastasis occurs late, is mainly found but not confined to the liver, and is associated with high morbidity, as >1/3 of pts do not qualify for further therapy.
  • Advances in MUM can only be achieved by networking of sites interested in this tumor with systematic collection of data and tissue to improve our understanding of the molecular biology of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Urba S, Schneider BJ, Hayman JA, Orringer M, Chang A, Pickens A, Pan C, Lee J, Foster J, Merajver S: Preoperative chemoradiation and postoperative adjuvant tetrathiomolybdate for patients with resectable esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 13 pts completed the full 24 mos of treatment, 12 completed 10-23 mos, 15 completed 2-8 mos, and 8 completed only 1 month or less.
  • 27 pts have had disease recurrence, the majority (23 of the 27) of which was distant.
  • Current status of pts with median follow-up time of 55 months: 25 alive and disease-free, 1 alive with disease, and 43 have died.
  • Disease-free survival and overall survival are promising when compared to historical controls treated with a very similar chemoradiation regimen without TM in the past at the University of Michigan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962224.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Markowicz S, Nowecki ZI, Rutkowski P, Lipkowski AW, Jakubowska-Mucka A, Switaj T, Biernacka M, Misicka A, Walewski JA, Ruka W: Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):9039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients.
  • : 9039 Background: This is a pilot study evaluating of high-risk melanoma patients (pts) treated with peptide-DC vaccine after lymphadenectomy (LND).
  • DC vaccination was designed to induce the immune response against melanoma antigens in melanoma pts who remain at high risk of dissemination after LND.
  • METHODS: DCs were generated from the bone marrow with the use GM-CSF, SCF, FLT3-L and TNFa or from peripheral blood adherent monocytes with GM-CSF and IL-4.
  • DCs pulsed with HLA-A2-binding TYR, MART-1 and gp100 peptides and/or HLA-A1-binding MAGE-1, MAGE-3 peptides, tumor lysate if available, or with tracer antigen keyhole limpet hemocyanin (KLH), were injected sc 9 times within 8 months (mos).
  • Boost injections were performed after 12 and 24 mos.
  • RESULTS: HLA-A2<sup>+</sup>, -A1<sup>+</sup> or -A3<sup>+</sup> melanoma pts (n=22), stage III, N1b-N3, enrolled between Sept.
  • Cutaneous delayed type hypersensitivity (DTH) to melanoma peptides was induced in 12 of 22 pts.
  • At least one of these responses to melanoma antigens was elicited in 17 of 22 pts.
  • Nine vaccinated pts are free of disease, and 1 is stable by Dec.
  • 2008 (follow up is 58-76 mos after LND).
  • CONCLUSIONS: The DC/peptide vaccine elicited immune responses to melanoma antigens.
  • Vaccinated pts had clinically substantially longer overall survival (OS) and disease free survival (DFS) than matched control.
  • OS was associated with the immune responsiveness to melanoma antigens and to KLH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):8503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.
  • METHODS: 72 patients (pts) with relapsed/refractory MM received 0.7 - 1.3 mg/m<sup>2</sup> Bz as IVB followed by 1-hr infusion of 100 -340 mg/m<sup>2</sup> Tan on days 1, 4, 8,11 q 21d, with 42 pts receiving the highest dose of both drugs as part of a phase II expansion.
  • RESULTS: Of 72 pts, 72% had IgG subtype with a median age of 60 yo.
  • Median time since MM diagnosis was 50 mos with median of 5 (1-15) prior regimens.
  • 58 pts with measurable disease were treated at 1 or 1.3 mg/m<sup>2</sup> Bz.
  • Median duration of response (DOR) for all pts with response (n=14) was 10.7 mos, including 3 Bz-refractory pts who had durable PR through mos 12, 22 and 28.
  • 3 other pts remain in response through 24 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • Cycles were repeated every 21 d up to 6 cycles or disease progression.
  • Among pts with (N=194) and without (N=941) BM, response rates=28.9% and 29.1%, median survival = 7.7 mos (95% CI: 6.7, 9.3) and 8.6 mos (95% CI: 7.9, 9.5), and median time to progression = 4.3 mos (95% CI: 3.4, 5.6) and 4.6 mos (95% CI: 4.2, 5.1), respectively.
  • Median survival among pts with BM was 7.6 mos for GC (N=66, 95% CI: 6.3, 10.1), 8.2 mos for GP (N=64, 95% CI: 4.6, 10.5), and 7.7 mos for PC (N=64, 95% CI: 6.1, 10.2). CONCLUSIONS:.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kantarjian H, Giles F, Bhalla K, Pinilla J, Larson RA, Gattermann N, Ottmann OG, Gallagher NJ, Baccarani M, leCoutre P: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
  • METHODS: Primary endpoint was major cytogenetic response (MCyR).
  • RESULTS: CML-CP pts (n = 321, 70% IM-resistant, 30% IM-intolerant with resistance) with a minimum follow-up of 19 months (mos) were evaluated; 72% were treated with ≥600 mg/day IM prior to enrollment.
  • Median duration of prior IM treatment was 32 (<1-94) mos.
  • 59% achieved an MCyR (2.8 mos median time to MCyR; 56% in IM-resistant, and 65% in IM-intolerant pts), including 73% of pts with a baseline CHR and 44% achieved a CCyR (41% in IM-resistant; 51% in IM-intolerant pts).
  • Responses were durable, with 78% pts maintaining MCyR at 24 mos.
  • Estimated OS rate was 88% at 24 mos.
  • Gr 3/4 non-hematologic AEs were infrequent: rash, headache, and diarrhea occurred in 2% of pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961402.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Bhatnagar B, Tiu RV, Gondek LP, O'Keefe C, Huh J, Advani AS, Sekeres MA, Maciejewski JP: Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7016 Background: Myeloproliferative disorders (MPD) and myelodysplastic syndromes (MDS) often have overlapping features resulting in unclassifiable cases (MDS-U and MDS/MPD-U).
  • METHODS: MDS-U (N = 17) and MDS/MPD-U (N = 61) patients were selected from an MDS database (N = 720, median age = 76, median follow-up = 42 mos).
  • MDS/MPD-U and MDS-U patients had similar OS and EFS (OS = 42 vs. 45 mos, p = 0.13; EFS = 42 vs. 45 mos p = 0.63).
  • Overall, patients with new SNP-A lesions had worse OS and EFS (OS = 41 mos vs NR, p = 0.07; EFS = 32 vs 112 mos, p = 0.07).
  • This technology will be helpful in refining diagnosis based on characteristic recurrent chromosomal lesions including UPD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961389.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Heng DY, Xie W, Regan MM, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott D, Rini BI, Choueiri TK: Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):5041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median (m) OS was 22 months (95% CI: 20.0-24.8) with a median follow-up of 25 months.
  • Four of the five PFs previously identified by MSKCC were independent predictors of short survival, including hemoglobin below the lower limit of normal (LLN) (p < 0.0001), corrected calcium above the upper limit of normal (ULN) (p = 0.0006), Karnofsky performance status <80% (p < 0.0001) and time from initial diagnosis to initiation of therapy ULN (pULN (p = 0.012) were independent adverse PFs.
  • Patients were assigned one point for each poor PF and were segregated into three risk categories: favorable-risk (0 PFs, n = 133) median OS (mOS) 37.0 months; intermediate-risk (1 - 2 PFs, n = 292) mOS 28.5 months; and poor-risk (3-6 PFs, n = 139) mOS 9.4 months (log rank p < 0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C: Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):9520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy.
  • However, these treatments increase bone resorption, leading to bone loss and fractures.
  • RANKL is a key mediator of osteoclast-mediated bone resorption.
  • METHODS: Two trials were conducted: a 24-mo BC study and a 36-mo PC study.
  • Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos.
  • The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study.
  • Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies.
  • Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints).
  • RESULTS: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964507.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Extent of surgery, local outcome, morbidity and response to therapy were analyzed; median follow-up is 22 mos.
  • RESULTS: Median treatment duration was 11 mos. (range 2-31 mos).
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Histologically, one pCR and 11 near CR/good PRs were found.
  • Two local recurrences were detected at 31 and 44 mos. postop.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Blinder VS, Patil S, Diamant A, Thind A, Maly R: Employment status among low-income Caucasian and Latina breast cancer survivors. J Clin Oncol; 2009 May 20;27(15_suppl):6612

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This is a prospective, longitudinal study of low-income, underserved breast cancer survivors who spoke English or Spanish, did not have metastatic disease, and were enrolled in the Medi-Cal Breast and Cervical Cancer Treatment Program.
  • We interviewed survivors at 6 mos., 18 mos., and 3 yrs. after diagnosis to assess changes in employment status.
  • The impact of independent variables including ethnicity, employment at diagnosis, job type, age, health status, and education was assessed using chi-square tests.
  • RESULTS: 666 survivors completed surveys at both 6 mos. and 3 yrs; 65% were Latina.
  • At diagnosis, 51% of Latinas and 59% of Caucasians were employed (p = 0.07), and among these, Latinas were less likely to be working at 6 and 18 mos. than Caucasians (27% vs. 47% at 6 mos., p = 0.002 and 45% vs. 59% at 18 mos., p = 0.026).
  • Job type at diagnosis was associated with RTW.
  • CONCLUSIONS: Employed low-income Latinas and Caucasians appear to follow different RTW trajectories after breast cancer, with fewer Latinas working at 6 and 18 mos.
  • Differences exist in job type between these populations; Caucasians have greater variation in job type and a trend toward greater likelihood of changing job type after breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Carducci MA, Armstrong DK, Collins C, Wang T, Schaefer S, Ermisch S, Musib LC, Nicol S, Thornton DE, Zhang Z: Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment. J Clin Oncol; 2009 May 20;27(15_suppl):3517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DLT was defined as C1: Grade (G)4 neutropenia ≥7 days, febrile neutropenia, G3 thrombocytopenia with bleeding or G4 thrombocytopenia; G3/G4 non-hematological toxicities, and toxicities associated with BV.
  • Nine of 43 pts (21%) had a response (CR, PR), 6 responses were in the ovarian subset (29%).
  • Median time to progression was 3.9 mos (range 0-19.2 mos) and 7.7 mos for ovarian pts (range 0.3-19.2 mos).
  • Overall, 43% remained on study without disease progression for >6 mos (51% of ovarian pts remained on study for >6 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961299.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Frankenthaler A, Lee M, Seery V, Renzi S, Kinnaman M, Liu V, Friedman E, Atkins MB, Cutaneous Oncology Program: Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma.
  • : 9070 Background: Melanoma has been reported to be susceptible to immune control.
  • Therefore, we hypothesized that concomitant immune suppression might impact the course of the disease.
  • METHODS: We examined the Beth Israel Deaconess Medical Center Cutaneous Oncology Program database for pts with immune suppression at the time of melanoma diagnosis.
  • The demographics and stage of these pts were compared to those in the database as a whole.
  • In addition, 3 controls matched for age, gender, stage and tumor location were identified for each case and disease outcome was compared between cases and controls.
  • RESULTS: 19 pts were identified with melanoma and concomitant immune suppression in a database of 1820 melanoma pts.
  • Melanoma stages at diagnosis were in situ 1, IB 7, IIA 1, IIB 1, IIIB 3, IIIC 5, and IV 1.
  • Compared to the database as a whole, cases were more likely to be female (84% vs 45%) and have a higher disease stage (42% stage IIIB/C vs 26%).
  • In addition, more cases appeared to have an amelanotic primary (21% vs. 5.4%) or an atypical mole syndrome (21% vs 10.2%).
  • For pts who relapsed, the cases had a shorter disease free interval (DFI) (2.1 vs 9.7 yrs) than the controls.
  • At a median f/up of 52 mos, 37% of the cases had relapsed and all of these pts had died.
  • At a median f/up of 76 mos, 30% of the controls had relapsed yet only 47% of these pts had died.
  • As a consequence, cases appeared more likely to have died of their disease than controls (42% vs 23%) (p=0.10).
  • CONCLUSIONS: Compared to the general melanoma population, pts with concomitant immune suppression appear more likely to be female, have an amelanotic primary or atypical mole syndrome and more advanced disease at presentation.
  • Thus, diagnosis and treatment of a primary melanoma at an early stage appears especially important in an immunosuppressed population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Gligorov J, Cals L, Tournigand C, Merad Z, Dutel J, Selle F, Zeghib N, Chibaudel B, Cvitkovic F: Gemcitabine-oxaliplatin combination (SEGEMOX) in anthracycline (A) and taxanes (T) pretreated metastatic breast cancer (MBC): Results from the GERCOR-SEGEMOX phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):1108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1108 Objectives: To evaluate efficacy and safety of SEGEMOX regimen for previously A and T pre-treated MBC patients.
  • METHODS: Forty-five women with MBC not eligible for A and/or T chemotherapy were enrolled on SEGEMOX study.
  • Visceral metastases were dominant site of disease (44% liver; 36% lung; 44% bone).
  • After a median of 7.7 cycles (3.5 months of treatment); the overall response rate (ORR) is 38% [95%CI; 23%-51%] [1 CR (2.2%) and 16 PR (35.6%)]; 33% of stable disease [95%CI; 17%-43%], 24.4% progressive disease with a clinical benefit (CB) of 71% [95%CI; 57%-85%].
  • The median progression free survival (PFS) is 7.1 months for responders and 4.8 months for patients with stable disease.
  • The all population median overall survival (OS) is 21.4 months with 22.7 months MOS for responders.
  • The most frequent non hematologic toxicities were represented by grade 3 peripheral neuropathy (Levi Scale) in 11.4% of the patients and grade 2 alopecia in 11.4%.
  • For the subgroup of hormone receptor negative MBC (n = 12) the ORR is 33% [95%CI; 2%-64%], CB 50% [95%CI; 16%-73%], PFS of 2.8 months and MOS of 12 months.
  • CONCLUSIONS: The SEGEMOX combination has relevant activity in A and T not eligible MBC patients, with a manageable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962168.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Borczuk AC, Chen J, Parikh F, Powell CA, Taub RN: Use of laser capture microdissection to derive poor prognosis gene expression signatures of epithelial abdominal malignant mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):e22098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of laser capture microdissection to derive poor prognosis gene expression signatures of epithelial abdominal malignant mesothelioma.
  • : e22098 Background: Prior work in abdominal malignant mesothelioma (AMM) has established a poor prognosis profile of biphasic AMM when compared to more favorable prognosis epithelial AMM.
  • It is evident, however, that epithelial AMM shows heterogeneity in biologic behavior and prognosis.
  • Given improvements in therapy and survival in AMM, stratification of patients with epithelial AMM into favorable and poor prognosis subgroups is desirable and gene expression profiles may provide poor prognosis signatures to further guide therapy.
  • METHODS: Favorable and poor prognosis subgroups were defined as 1000 days of survival time (based on median survival of 90 patients with AMM at Columbia Presbyterian as of Sept 2007).
  • Fourteen frozen epithelial AMM (7 favorable prognosis, 7 poor prognosis) with high quality RNA were laser capture microdissected using a PALM Zeiss microscope and analyzed using Affymetrix U133 Plus 2 microarrays.
  • High expression of Nde1, UHRF1, and EZH2 by qPCR on a set of 32 AMM (using an upper quartile cutoff) was associated with poor survival (Log rank statistic p<.01, p<.003 and p<.03 respectively).
  • Immunohistochemistry performed on tissue microarrays of 122 AMM for p16 loss and increased EZH2, Col3A1 and UHRF1 immunoreactivity was associated with poor survival (Log rank statistic p<.0001, p<.009, p<.0001 and p<.012, respectively).
  • CONCLUSIONS: Using a training set of laser captured favorable and poor prognosis epithelial AMM, a 39-gene signature was obtained that is associated with prognosis.
  • Validation of several of the candidate genes by qPCR expression and immunohistochemistry was performed, confirming favorable and poor prognosis strata among the epithelial AMM.
  • Identification of poor prognosis epithelial AMM at the time of initial biopsy/tumor cytoreduction could lead to more aggressive primary therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963284.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Hussain A, Onukwugha E, Seal B, Mullins CD: Visit and treatment patterns over time among elderly patients (pts) with M1 prostate cancer (PC): An analysis using SEER-Medicare. J Clin Oncol; 2009 May 20;27(15_suppl):5170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study included pts with a post-diagnosis visit to a urologist; pts who saw a MOH prior to the urologist visit were excluded.
  • Pts were grouped as 1) no MOH visit, 2) MOH visit w/in 3 mos of a urologist visit, 3) MOH visit => 3 mos after a urologist visit.
  • 2) timely (i.e. within 6 mos of diagnosis); and 3) delayed, i.e.
  • => 6 mos following the diagnosis.
  • CONCLUSIONS: Approximately one-third of patients with M1 disease and a post-diagnosis urologist visit also see a medical oncologist.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT: MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):e13023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The logrank test was used to compare mPFS and mOS in patients who had methylated (ME) MGMT vs. unmethylated (UN) MGMT.
  • ME was associated with a significantly prolonged mPFS and mOS as noted in the table below which also summarizes the characteristics of the study population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962794.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Pennell NA, Videtic GM, Murthy S, Mason D, Rice TW, Mazzone P, Samsa J, Rich T, Shapiro M, Mekhail T: A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC).
  • Non-progressors underwent resection followed by the same CRT regimen and 2 years of mE (150mg).
  • The primary endpoint of the phase I portion was the maximum tolerated dose (MTD) of E given with CRT; and for the phase II was safety and tolerability.
  • At a median follow-up of 36.5 mos the median PFS is 41.8 mos (95% CI 9.3-not yet reached).
  • Pts downstaged to pN0-1 vs those with persistent pN2-3 had a median PFS of 41.8 vs 18.1 mos (p=0.11).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R: Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). J Clin Oncol; 2009 May 20;27(15_suppl):e19006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).
  • EGFR activating mutations correlate with adenocarcinoma histology, non-smoking history, female gender, and Asian ethnicity.
  • It has also been determined that EGFR and met can crosstalk, and serve as potential mechanism of resistance in NSCLC.
  • We will correlate these data with EGFR mutation and c-Met expression/mutations/amplifications for markers of NSCLC.
  • Overall response rate of 13.6% (6-PR, 16-SD, 18-progessive disease, and 4 patients lost to follow up).
  • The PFS was 4.0 months; 95% CI: (2.5-6.6 mos) and overall survival 8.6 mos; 95% CI: (7.2-30.9 mos).
  • EGFR mutations and c-Met analysis will be provided by ASCO meeting in May 2009.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Gitlitz BJ, Davies AM, Belani CP, Argiris A, Ramalingam SS, Hoffman PC, Koczwas M, Groshen SG, Gandara DR: A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial. J Clin Oncol; 2009 May 20;27(15_suppl):8056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial.
  • METHODS: Eligible pts included: histologically confirmed advanced NSCLC, previous treatment with platinum-based therapy and a taxane, no more than 2 prior regimens, measurable disease, Zubrod performance status ≤ 2.
  • TREATMENT: E7389 1.4 mg/m<sup>2</sup> intravenously over 1-2 minutes on day 1 and 8 of a 21 day schedule until disease progression or unacceptable toxicity.
  • Stable disease rate was 60% and 24% in TS and TR pts. respectively.
  • Median progression free survival (PFS) is 6.3 mos TS pts.
  • 95%CI (2.5-8.6 mos) and 1.2 mos TR pts.
  • 95%CI (1.1-4.1 mos).
  • Major toxicity included: 19 pts (46%) with grade 3 or 4 hematologic toxicity including only 1 episode of febrile neutropenia and 8 pts (20%) with grade 3 or 4 non-hematologic toxicity attributable to drug including: fatigue (1), dehydration (2), nausea (2), constipation (2).
  • CONCLUSIONS: E7389 was well tolerated with encouraging objective response, PFS and disease control rate in the TS cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Goodman LJ, Weston JK, Mukherjee A, Sperinde J, Paquet A, Williams S, Parry G, Bates M, Koestler W, Lipton A: Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A previously reported H2T cutoff was used to sub-divide the patients into HER2-normal (N = 26, median TTP = 4.1 mos) and HER2-overexpressing (N = 55, median TTP = 11.1 mos, HR = 0.43, p = 0.0002) groups.
  • In the HER2-overexpressing group, high H3T expression, as defined by a positional scanning cutoff analysis, predicted shorter median time to progression (N = 25, median TTP = 6.1 mos) compared with low H3T expression (N = 30, median TTP = 13.1 mos, HR = 2.7, p = 0.0002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961045.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Onukwugha E, Mullins CD, Obeidat N, Seal B, Hussain A: The impact of docetaxel (D) in an older population of patients with advanced prostate cancer (PC): A simulation study using TAX327 and SEER Medicare data. J Clin Oncol; 2009 May 20;27(15_suppl):e16074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16074 Background: The survival benefit of D in treatment of hormone refractory PC (HRPC) has been established in the TAX327 trial, but it is unclear how this benefit would translate in a heterogeneous population.
  • This study sought to simulate the survival impact of D in a population of older pts with M1 PC on androgen deprivation therapy (ADT).
  • The simulated benefit was assessed at 12 mos and 24 mos post-diagnosis of M1 PC in SM pts.
  • Median survival was 15.7 mos (12.6 - 19) in the M arm and 18.9 mos [17 - 21.8] in the D3P arm (p = 0.03).
  • Median survival benefit of D was 3.2 mos based on Kaplan-Meier estimates and 2.4 mos using parametric curves in the TAX327 69+ group.
  • Following covariate-adjustment in the SM sample, at 12 mos post-diagnosis, the median survival in mos was 61.7 (CI 36.3 - 87) in the ADT group and 62 (CI 37.6 - 87.1) in the simulated ADT+D group (i.e., 0.3 mos simulated benefit of D).
  • A 0.8 mos simulated benefit was found if D was initiated 24 mos post diagnosis (in pts more likely to have HRPC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963046.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM: Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol; 2009 May 20;27(15_suppl):e16035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median overall survival (OS) time of pts treated with interferon alfa (IFN-α) without CN was 7.8 months (mos) [Flanigan et al.
  • We calculated OS time from date of diagnosis until date of death or last follow up.
  • We excluded pts who had embolization, radiofrequency ablation or cryotherapy of the primary tumor.
  • Median follow-up time is 9.7 mos (range: 1.2-49.2).
  • Median OS time for all pts is 10.7 mos (95% CI: 7.6-15.4).
  • 55 pts (62.5%) had clear-cell and 33 (37.5%) had non-clear cell histology, with median OS times of 15.1 mos (95% CI: 9.6-17.7) and 7.4 mos (95% CI: 4.4-13.0), respectively.
  • ECOG performance status (PS) at time of diagnosis was correlated with OS (HR 1.54; 95% CI: 1.16-2.05; p<0.01).
  • Pts with PS 0, 1, 2, and 3 had median OS times of 22.8 mos (95% CI: 5.7,*), 16.5 mos (95% CI: 8.1-24.7), 7.6 mos (95% CI: 5.7-11.9), and 7.1 mos (95% CI: 3.3-9.6), respectively.
  • Pts with clinical evidence of lymph node (LN) involvement had worse outcome,with median OS time of 7.6 mos (95% CI: 5.6-9.8) versus 17.2 mos (95% CI: 9.8-35.5) for pts without clinical evidence of LN involvement.
  • CONCLUSIONS: In this analysis, median OS time for pts with mRCC treated in the modern era with TT without CN is superior to historical experience with IFN- α.Compromised PS, LN involvement, and non-clear cell histology were associated with worse outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement